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ABSTRACT  
Type 1 diabetes is a chronic autoimmune disease that leads to apoptosis and death of
pancreatic islet beta cells. These beta cells are influenced by and contribute to a network
of gut derived hormones that regulate glucose homeostasis. Our research explores the
effect that type 1 diabetes has on this network of gut hormones. A series of clinical
research studies was established to collect samples from both healthy participants and
individuals with type 1 diabetes. Methods to measure gut hormones were explored and
refined prior to sample analysis. Results from this analysis revealed that the homeostasis
of glucagon, active-ghrelin and peptide YY are affected by type 1 diabetes and that
glucagon secretion may be controlled by a glucose independent signal derived from the
gut.  Important  lifestyle  markers  in  type  1  diabetes  were  identified  and  included  a
correlation between leptin and body mass index and gastric inhibitory polypeptide and
sedentary behaviour. Histopathological analysis of pancreatic slides taken from donors
with type 1 diabetes suggest that the islet area stained for glucagon does not correlate
with duration of diabetes, but does correlate with age. Together these suggest that type 1
diabetes does affect other gut hormones involved in glucose homeostasis and this can be
influenced by lifestyle factors.
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1. INTRODUCTION  
Diabetes mellitus is a term for a group of metabolic conditions characterised by a higher
than  normal  glucose  level.  According  to  the  World  Health  Organisation  ICD-10
classification, there are five forms of diabetes 1) type 1 diabetes mellitus,  2) type 2
diabetes mellitus, 3) Malnutrition related diabetes mellitus, 4) Other specified diabetes
mellitus and 5) Unspecified diabetes mellitus [1]. Diabetes mellitus, if left uncontrolled
with hyperglycaemia and glycaemic variability, results in increased microvascular and
macrovascular complications.  Diabetes and its complications are estimated to cost the
NHS over £20 billion per year and affect nearly 4 million individuals in the UK alone
[2]. Type 1 diabetes is the second most common form of diabetes after type 2 diabetes,
with a UK prevalence of ~600 cases per 100,000 population. The prevalence of new
cases of type 1 diabetes is approximately 20 per 100,000 [3]. However, the prevalence
of type 1 diabetes varies from country to country with the highest incidence in the
Scandinavian  countries  (>50  per  100,000)  and  the  lowest  incidence  in  Far  Eastern
countries (<5 per 100,000).   
The  majority  of  new cases  of  type  1  diabetes  appear  around  puberty  with  rapidly
declining  new cases  appearing  in  adulthood.  Symptoms  of  polyuria  and  polydipsia,
typical of type 1 diabetes are said to occur when approximately 90% of insulin secreting
pancreatic beta cells stop functioning [4]. As insulin levels decline, the body's ability to
utilise sugars for either metabolism or storage declines. Failure to utilise glucose results
in  an  increase  in  blood  glucose  levels  (hyperglycaemia).  As  blood  glucose  levels
increase, glucose enters the urine leading to the osmotic symptom of excessive urination
and subsequent thirst. Ultimately, the failure to utilise glucose for energy leads to fatty
acid metabolism and formation of ketone bodies. Thus, individuals with new onset type
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1 diabetes develop ketosis and dehydration that, without an external source of insulin
being administered, could be life threatening [5]. 
1.1 Historical insight into diabetes
“Diabetes” was coined by Apollonius of Memphis in 250BC, from the Ionian Greek for
“passing  through”,  which  describes  the  frequent  micturition  (polyuria)  that  leads  to
dehydration and death. In 1921, Professor John Macleod at the University of Toronto
was  approached  by  a  Canadian  born  surgeon  Frederick  Banting  with  an  idea  of
extracting anti-diabetic secretions from the pancreas. Working with the English born
medical student Charles Best, they were able to isolate pancreatic extract and use it to
treat diabetes in a dog. They then went on to use cattle pancreas extract and proved this
also was effective treating diabetes in a dog. On the 1st January 1922 they used bovine
pancreatic extract in a human diabetic subject, but unfortunately it was unsuccessful.
The biochemist James Collip, who was also part of the research team, was able to refine
the extraction and purification process of the bovine insulin. On the 23rd January 1922
the first human subject with type 1 diabetes was successfully treated with injectable
insulin.
Before the 23rd January 1922 the main treatment for individuals with type 1 diabetes
was a  severely  calorie  restricted  diet  [6].  It  was  not  very  effective,  with  many not
surviving more than a year. However, it was successful in a small group of individuals,
some of which went on to receive Macleod, Banting,  Best and Collip's new bovine
insulin.  Current treatment strategies for type 1 diabetes have not changed much and
include either injectable insulin or using an automated device with an insulin reservoir.
Only recently have advances allowed the use of donor islet cells to replace beta cells
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lost in type 1 diabetes. The publication of the Edmonton protocol in 2000 heralded a
new era in islet cell transplant as it resulted in exogenous insulin independence [7]. It is
hoped that better understanding of the pathophysiology of type 1 diabetes may lead to
treatments that inhibit beta cell apoptosis and preserve beta cell function.  
1.2 Glucose Transport
Glucose transport in and out of cells in humans is controlled through three families of
glucose transporter proteins known as the SLC5, SLC2 and SLC50 genetic families [8],
[9]. 
The SLC5 family of glucose transporters is encoded by multiple genes, with the most
prominent being the Na/Glucose Like Transporters (SGLT1 and SGLT2).  The SGLT2
transporter in the kidney is key in enabling the re-absorption of 90% of glucose through
the renal tubules. It is a prominent target of recent drug development in the treatment of
type 2 diabetes. SGLT2 inhibition results in improved glycaemia through inhibiting the
re-absorption of glucose in the renal tubule. This increases glucose loss in the urine
(glycosuria) and lowers plasma glucose levels. However, SGLT2 inhibitors also cause a
paradoxical increase in hepatic gluconeogenesis and glucagon secretion. It is thought
that the increase in glucagon secretion is due to up regulation of SGLT1 receptors on the
alpha cells. SGLT1 inhibitors have been shown to increase GLP-1 which could have
benefit in improving glucose sensitivity and increasing insulin secretion [10].  
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SLC5 family Substrate Tissue
5A1 (SGLT1) Glucose and 
galactose
Small intestine, trachea, kidney, heart, 
brain, testes and prostate.
5A2 (SGLT2) Glucose Kidney, brain, liver, heart muscle, thyroid 
and salivary gland.
5A4 (SGLT3) Sodium Small intestine (cholinergic neurons), 
skeletal muscle, kidney, uterus and testis.
5A8 (SMCT1) Short fatty chain 
acids
Small intestine, kidney, brain, retina, and 
muscle.
Table 1.1: Table of SLC5 family of glucose transporters.
The SLC2 family encodes receptors involved in monosaccraharides transport across the
cellular membrane via the glucose/hextose transporters (GLUT). The GLUT family of
integral  membrane  proteins  can  be  subdivided  into  three  classes  of  transporters  of
similar  structure.  Every  cell  of  the  human  body  contains  a  SCL2  genetic  family
glucose/hextose transporter.
SLC2 family Substrate Location
GLUT1 Glucose, galactose, mannose Red cells, brain, blood-tissue 
interfaces, Islets of Langerhans, 
kidney,
GLUT2 Glucose, galactose, fructose, 
mannose, glucosamine
Liver, intestine, Islets of Langerhans, 
kidney, brain
GLUT 3 Glucose, galactose, mannose,
xylose.
Islets of Langerhans, neurones, testes
GLUT4 Glucose, glucosamine Adipose tissue, skeletal and cardiac 
muscle.
GLUT5 Fructose Small intestine, kidney
Table 1.2 Table of SLC2 family of glucose transporters.
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Chronic high levels of monosaccharide and lipids have been shown in rodent models to
down regulate the GLUT2 receptors on Beta Cells. It is hypothesised that this results in
the down regulation of glucose stimulated insulin secretion. It has also been suggested
that  GLUT2  down  regulation  also  impacts  on  hypoglycaemia  stimulated  glucagon
secretion  [11],  [12].  The  GLUT4  transporter  is  the  main  transporter  involved  in
increasing glucose uptake into muscle and adipose cells. GLUT4 is insulin sensitive and
its  cellular  expression  is  also  up-regulated  by  insulin.  Thus,  defects  in  GLUT4
expression could contribute to insulin resistance which may form part of the mechanism
leading  to  type  2  diabetes.  Reduced  expression  of  GLUT4  has  been  shown  to  be
induced by the protease inhibitor class of drugs which can induce a form of insulin
resistant drug induced diabetes in HIV patients.
The  SLC50 class  of  co-transporters  are  relatively  new and  predominantly  found  in
plants. However the SLC50A1 (SWEET1) transport is involved in glucose transport in
humans.   SCL50A1 is  highly  expressed  in  the  liver,  kidney,  exocrine  pancreas  and
Leydig cells. Its importance in glucose homeostasis is still relatively unknown [9]. 
1.3 Insulin homeostasis
The pancreatic islets are composed of multiple cells that release a variety of hormones.
One of the most prominent hormones that they secrete is insulin which is produced in
the beta cells. Insulin is a polypeptide hormone composed of two chains (A- and B-
chain) [13]. It is initially synthesised as preproinsulin and is converted to proinsulin as it
enters the endoplasmic reticulum of the cell. Proinsulin is then cleaved by prohormone
convertases and carboxypeptidases into insulin and C-peptide, before being stored as
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mature granules which are subsequently released following a stimulus. Insulin release
occurs in two phases, the first is dependent on the activation of glucose transporters, the
second phase is  independent  of  these glucose transporters.  The release of insulin  is
pulsatile with a frequency of 1 pulse every 3-6 minutes [14]. The target of insulin is the
insulin receptor. The insulin receptor is involved in activation of increased expression of
GLUT4.  GLUT4  increases  glucose  uptake  into  hepatocytes  where  glucokinase
(hexokinase in other cells) phosphorylates glucose to glucose-6-phosphate, which can
then either enter glycolysis or be polymerized to glycogen for storage. 
  
1.4 Glucagon homeostasis
1.4.1 History of Glucagon
The history of the alpha cell closely mirrors that of the beta cell. In 1869, a 22 year old
German medical  student,  Paul  Langerhans,  identified  an island of  clear  cells  in  the
pancreas, later named “The Islets of Langerhans”  [15], [16]. In 1907 another medical
student, Michael Lane discovered that there were two distinct cell types in the islets,
which he went on to term the alpha and beta cell [17]. Charles Best, whilst working as a
medical student for Dr Fredrick Banting, noted that when the early crude extracts of
canine pancreas were administered to diabetic dogs, there was an early rise in blood
glucose,  before  subsequent  hypoglycaemia.  Finally,  in  1923  Charles  Kimball,  a
biochemistry student, isolated a substance from the alpha cell and named it “glucagon”
[18]. In 1957 the amino acid sequence was elucidated by a team of biomedical scientists
at the Lilly Research Laboratories.     
1.4.2 Physiology of alpha cells
Immuno-histochemically, the alpha cell is defined by the presence of glucagon staining,
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and the secretion of glucagon is considered to be the primary role of the alpha cell [19].
Glucagon targets the glucagon g-protein coupled receptor that stimulates glycogenolysis
and  gluconeogenesis,  and  decreases  glycogenesis  and  glycolysis  [20]–[22].
Glycogenolysis of glycogen stores primarily occurs in the liver, but can also occur in
muscle.  However,  the  concentrations  in  the  hepatic  portal  system  are  significantly
higher than those in the systemic circulation. Glycogenolysis involves the breakdown of
glycogen stores to glucose-1-phosphate and subsequently to glucose, thus raising blood
glucose levels. Gluconeogenesis is an alternative pathway, releasing glucose from non-
carbohydrate metabolic stores (see figure 1.1).
Figure 1.1: Carbohydrate metabolic pathway.
Glucagon is a 29 amino acid sequence peptide involved in glucose homeostasis. It is
cleaved from the larger proglucagon peptide by a prohormone convertase. It primarily
affects glycogen storage in the liver, with the subsequent release of glucose.  Glucagon,
along with the Glucagon related peptides, bind specifically to the B1 class G-protein
coupled receptor (GPCR) family. This is an evolutionarily conserved receptor family
which includes receptors that bind to Glucagon, Gastric Inhibitory Polypeptide (GIP).
Glucagon  Like  Peptide  -1  (GLP-1),  Glucagon  Like  Peptide-2  (GLP-2),  Vasoactive
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Intestinal  Peptide  (VIP),  Secretin,  Calcitonin,  Corticotrophin  releasing  hormone
peptides (CRH), Pituitary adenylate cyclase-activating peptide (PACAP) and Growth
hormone-releasing  hormone  (GHRH).  These  receptors  have  a  seven  transmembrane
structure with a long N-terminal extracellular domain which contains the primary ligand
binding site. This group of receptors appear to be influenced by the accessory peptides
Receptor Activity Modifying Protein (RAMP). In particular the glucagon receptor is
influenced  by  RAMP2.  Stimulation  of  the  glucagon  receptor  activates  adenylate
cyclase, resulting in an increase in cAMP that leads to activation of protein kinase A
(PKA).  Protein kinase A causes stored glycogen breakdown through glycogenolysis in
order to release glucose for energy utilisation. 
The proglucagon gene was isolated in 1983, four years after the insulin gene was first
sequenced  [23]. The proglucagon gene encodes glucagon, as well as oxyntomodulin,
glicentin and glucagon like peptides 1 and 2 (GLP-1 and 2). The gene is expressed
primarily by pancreatic alpha cells, intestinal L-cells as well  as some neuronal cells
[24]–[26].  However,  these  cells  differ  in  how  the  pro-peptide  is  processed  by  the
enzyme  prohormone  convertase  (PC).  PC1/3  is  predominantly  expressed  in  the
intestinal L-cells and cleaves proglucagon to release GLP-1, GLP-2 and oxyntomodulin.
PC2 is predominantly expressed in pancreatic alpha cells and the glucagon secreting
enteroendocrine cells of the stomach, and cleaves proglucagon to release glucagon [27]–
[32]. 
Alpha cells release glucagon in response to two distinct pathways: glucose dependent
and hormone dependent. The glucose dependent pathway stimulates glucagon release
through  the  formation  of  calcium  channel-SNARE  protein  complexes  resulting  in
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glucagon  granule  exocytosis  [33].  The  intracellular  mechanisms  involved  in  the
hormone dependent pathway are currently unknown, but probably mediated by Protein
Kinase C (PKC) [34], [35]. The hormones involved in this pathway are produced and
mediated  via  a  complex  hormonal  network  involving  the  liver,  intestine,  nervous
system, muscular and adipose tissue (e.g. hepato-enteral, neuronal, adipo-muscular, Islet
(HENAMI) endocrine network)  (see Figure 1.2).  The function of this  network is  to
regulate the storage and utilisation of energy. The Islets of Langerhans are a key part of
this network and are composed of five distinct endocrine cells (see Figure 1.3): alpha
cells  secreting  glucagon,  glucagon  like  peptide  1  (GLP-1)  and  glucose-dependent
insulinotropic  peptide  (GIP);  beta  cells  secreting  insulin  and  amylin;  delta  cells
secreting somatostatin; epsilon cells secreting ghrelin and the PP cells (also known as F
cells) secreting pancreatic polypeptide and small quantities of peptide YY (PYY) [36]–
[39]. All islet cells receive and secrete hormones either locally into the islet interstitium
(paracrine) or regionally via the intra-islet capillaries into the hepatic portal circulation
(endocrine). The islet cells also receive signals from the brain and possibly the intestine
via  neuronal  innervation  [40]–[44].  Hormone  dependent  stimulation  of  alpha  cell
secretion of glucagon is principally controlled by paracrine signals from the Islets of
Langerhans, in particular from the beta cells and delta cells [45]–[48]. 
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Figure  1.2:  HENAMI  –  (hepato-enteral,  neuronal,  adipo-muscular,  islet)  hormonal
network.
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Figure 1.3: Cells of the Islets of Langerhans
In health, a postprandial rise in blood glucose activates both a glucose mediated and
beta cell derived hormone mediated inhibition of glucagon release from the alpha cells.
This in turn inhibits hepatic glucose release[20]. Conversely, low blood glucose inhibits
the  beta  cell  derived  inhibition  of  glucagon  secretion,  thus  the  alpha  cell  releases
glucagon, resulting in hepatic glucose release.
The  intestine  also  secretes  other  hormones  involved in  the  HENAMI network.  The
intestinal L cells secrete glucagon like peptide -1 (GLP-1) and glucagon like peptide – 2
in equimolar concentrations. GLP-1 inhibits  alpha cell  secretion of glucagon. It  also
stimulates  beta  cell  secretion  of  insulin  and  inhibits  beta  cell  apoptosis.  GLP-2
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stimulates both intestinal cell growth and  alpha cell secretion of glucagon  [49]–[54].
The mechanism that controls the balance between GLP-1 and GLP-2 signalling in alpha
cells  is  unknown.  The  intestinal  K  cells  secrete  GIP  which  stimulates  alpha  cell
secretion of glucagon and possesses  anti-apoptotic  beta  cell  properties  [55]–[57].  In
healthy humans GIP  administration results in a dose dependent increase in glucagon
secretion from alpha cells [58]. The PC2 expressing alpha cells have also been found to
secrete a truncated form of GIP [59]. Both forms of GIP are biologically active, but their
mode of action may vary.   
The intestinal P/D1 and X/A-like cells found in the stomach's oxyntic glands express the
proghrelin  peptide  [39],  [60]–[63].  These  cells  cleave  proghrelin  and  secrete  it  as
acylated-ghrelin, unacylated-ghrelin and obestatin [64], [65]. Acylated-ghrelin can bind
to receptors on the alpha cell to stimulate glucagon secretion and act on the brain to
stimulate hunger  [66]. Leptin is secreted by adipocytes and has the opposite action to
ghrelin by inhibiting alpha cell secretion of glucagon and decreasing hunger [67]–[71].
Leptin is closely related to IL-6 which is released from muscle tissue in response to
exercise  [72],  [73]. Il-6 can also stimulate alpha cells to secrete a small  quantity of
GLP-1, which stimulates beta cell secretion of insulin [74].
1.4.3 Glucagon function in type 1 diabetes
In type 1 diabetes the loss of beta cells results in failure to inhibit alpha cell secretion of
glucagon.  This  results  in  persistent  hyperglucagonaemia  that  drives  the  release  of
glucose from hepatic stores [75], [76].  In severe insulin deficient hyperglycaemia the
systemic blood glucagon concentration causes the release of glucose from muscle stores
and  stimulates  lipolysis  in  adipose  tissue.  This  can  lead  to  ketone  formation  and
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clinically to diabetic ketoacidosis [77]–[79].
In paediatric case studies of new onset type 1 diabetes, there is a 45% decline in meal-
stimulated C-peptide, and a reciprocal 37% rise in glucagon levels within the first year
[80].  Other  studies  have  found  that  whilst  glucagon  suppression  to  an  intravenous
glucose challenge remains intact in type 1 diabetes, there is a 0-30 minute increase in
glucagon  secretion  before  suppression  to  an  oral  glucose  challenge  [81]–[83].  This
suggests that intestinal derived factors influence glucagon secretion in type 1 diabetes,
but not in individuals with preserved beta cell function.  Conversely a study in type 1
diabetes  found  that  insulin  induced  hypoglycaemia  failed  to  significantly  stimulate
glucagon release at a median of 8 months after diagnosis, whilst arginine stimulated
glucagon release remained intact. The pathophysiology for this remains unknown, but
may  be  due  to  desensitisation  in  the  glucose  dependent  mechanism  that  controls
glucagon  exocytosis.  Clinically  this  leads  to  an  impairment  in  response  to
hypoglycaemia in individuals with type 1 diabetes [84]–[86].
1.4.4 Current drugs that target glucagon secretion.
High dose glucagon is used in clinical practice to treat severe disabling hypoglycaemia
in type 1 diabetes and historically in treating beta blocker overdose [87]. In a trial of 15
participants with type 1 diabetes the use of a combined glucagon and insulin closed loop
delivery  system  improved  glycaemic  control,  decreased  episodes  and  time  in
hypoglycaemia [88], [89]. Unfortunately, currently purified glucagon peptide degrades
rapidly  and forms  amyloidogenic  fibrils,  but  synthetic  glucagon analogues  have  the
potential  to  last  longer  [90].  In  the  future  synthetic  glucagon  analogues  have  the
potential to be used in dual hormone closed loop systems [91]. 
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Activation  of  the  g-protein  coupled  GLP-1 receptor  on  some pancreatic  alpha  cells
results in a reduction in glucagon secretion [14], [92]. GLP1 stimulation of beta cells,
and the paracrine effects of the resulting insulin secretion on adjacent alpha cells lead to
a decrease in glucagon secretion. Thus, clinically approved drugs that target the incretin
pathway  (i.e.  GLP-1  agonists  and  DPP-4  inhibitors)  exert  some  of  their  glycaemic
effects through the reduction in alpha cell secretion of glucagon, thus reducing release
of hepatic glucose.  These drugs have now established themselves as important agents in
the treatment of type 2 diabetes.
Exploratory trials of the use of GLP-1 analogues in individuals with type 1 diabetes
suggest there may be glycaemic benefit (see Figure 1.4) [93]–[96]. This benefit persists
in  the  absence  of  detectable  C-peptide,  suggesting  GLP-1  agonists  exert  a  direct
inhibitory  effect  on  the  alpha-cells  or  through an  as  of  yet  unexplored  mechanism.
These trials also show reduced insulin requirements in individuals with type 1 diabetes,
without  an  increase  in  hypoglycaemic  episodes,  as  well  as  weight  loss.  GLP-1
analogues  are  not  currently  licensed  in  type  1  diabetes  by  the  US  Food  &  Drug
Administration  (FDA)  or  European  Medicines  Authority  (EMA).  However,  a  large
international trial into the effects of GLP-1 agonists in type 1 diabetes is under way.
Drugs  that  inhibit  the  enzyme  DPP-4  from  degrading  endogenous  GLP-1  are  also
widely used in clinical practice for type 2 diabetes. Vildagliptin and Sitagliptin have
undergone trials in individuals with type 1 diabetes resulting in a reduction in glucagon
levels and improvements in postprandial glycaemia (see Figure 1.5) [97]–[107]. DPP-4
inhibitors are not currently licensed in type 1 diabetes by the FDA or EMA.
14
Table 1.3 GLP-1 inhibitors in type 1 diabetes
Study Study Design Intervention HbA1c(%) Effect
Garg 2012
Ellis 2011 N/A
N/A
Meal stimulated Glucagon 
effect
16 week double-blind, 
randomized placebo-controlled 
 parallel study (n=125)
Sitagliptin 100mg 
OD or Placebo
Change from baseline: 
Sitagliptin 100mg vs 
Placebo;  -0.07 +/- 0.7 vs 
-0.12 +/- 0.75,  p>0.05
4 hrs AUC (pg/ml.min) 
Sitagliptin vs Placebo: 84.7 ± 
23.6 vs 84.9 ± 35.3,  
p>0.05
Farngren 
2012
4 week double-blind, 
randomized, placebo-
controlled crossover study 
(n=28)
Vildagliptin 50mg 
BD or Placebo
Difference between 4 weeks: 
Vildagliptin vs Placebo; 
-0.32 +/- 0.09%, p<0.005 
2hr AUC (nmol/l.min) 
Vildagliptin vs Placebo: 2.4 
+/- 0.2 vs. 2.6 +/- 0.2, 
p<0.05
4 week double-blind, 
randomized, placebo-
controlled  crossover study 
(n=20)
Sitagliptin 100mg 
OD or Placebo
Difference between 4 weeks: 
Sitagliptin vs Placebo; -0.27 
+/- 0.11%, p<0.05
Foley 
2008
4 week double blind, 
randomised, placebo-
controlled,  cross-over trial 
(n=12)
Vildagliptin 
100mg BD or 
Placebo.
1hr AUC (mcg/l.min) 
Vildagliptin vs Placebo: 
-0.2+/-0.6 vs 1.9+/- 0.6, 
p<0.05
Table 1.4: DPP-4 inhibitors in type 1 diabetes
1.4.5 Future drugs that might target glucagon secretion
The number of identified target receptors that regulate alpha cell function has increased
over the last decade.  The development of novel dual GLP-1/Glucagon receptor and
GLP-1/GIP receptor targeted peptides have been shown to treat hyperglycaemia in mice.
Ghrelin antagonists which decrease alpha cell secretion of glucagon in type 1 diabetes
have been shown to improve glycaemic control in non-human studies [108]–[111]. The
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Study Study Design Intervention HbA1c(%) Effect
N/A
N/A
N/A No statistical difference
Meal stimulated Glucagon 
effect
Varanasi 
2011
24 week open labelled,cohort 
study (n=8)
Liraglutide 
variable dose
Baseline vs 24 weeks:  6.5 
vs 6.1, p<0.05
Kielgast 
2011
4 week open-labelled, cohort 
study (n=29)
Liraglutide 1.2mg 
OD
Baseline vs 4 weeks: C-
peptide +ve on liraglutide 
(n=10 ) 6.6+/-0.3 vs 6.4+/-
0.3, p<0.05; C-peptide -ve 
on liraglutide (n= 9) 7.5+/-
0.2 vs 7.0+/-0.1, p<0.05; 
C-peptide -ve not on 
liraglutide (n=10 ) 7.1+/-0.3 
vs 6.9+/-0.2, p>0.05  
Raman 
2010
Single Dose double-blinded, 
randomised, placebo controlled 
study (n=8)
Exenatide 
1.25μg – 2.5μg 
or Placebo
infusion  of  a  leptin  related  peptide  in  mice  models  of  type  1  diabetes  prevented
hyperglucagonaemia  and  improved  glycaemic  control  [112].  The  leptin  analogue,
Metreleptin has now entered phase 1 clinical trials in patients with type 1 diabetes.  A
group of novel drugs that target the cannabinoid receptor GPR119 have shown promise
in protecting mice alpha and beta cells from streptozotocin induced apoptosis that leads
to type 1 diabetes [113].  
Tocilizumab,  an  Il-6  receptor  monoclonal  antibody,  showed  an  improvement  in
glycaemic control when used in rheumatoid arthritis patients with concomitant diabetes
[114]–[116].  Il-6  is  also  a  marker  of  inflammation  and  a  constant  low  grade
inflammatory  process  may  accelerate  the  micro-vascular  and  macro-vascular
complications  of  type  1  diabetes  [117].  Acute  changes  in  Il-6  may  act  through
increasing gut expression of GLP-1  [118]–[121]. Thus, there may be future scope in
using the Il-6 receptor in regulating alpha cell secretion of glucagon and reducing rates
of micro-vascular complications. 
Probably the most exciting new drugs in development are those that act  directly on
glucagon receptor signalling. Lee et al, subjected glucagon receptor knock-out mice and
wild-type mice to  two doses of streptozotocin  [122].  The wild-type mice developed
hyperglycaemic ketoacidosis, whilst the glucagon receptor knock-out mice maintained
normal fasting glucose levels and did not develop ketoacidosis nor diabetes. This opens
the possibility of novel treatments through disruption of glucagon receptor signalling to
prevent  the  hyperglycaemia  of  type  1  diabetes  [123],  [124].  Similarly  non-diabetic
monkeys given glucagon receptor blocking antibodies showed a reduced blood glucose
level in a dose dependent manner [125]. The antibody was also given in higher doses to
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ob/ob mice and was successful in suppressing their hyperglycaemia [124]–[126].
1.5 Other Gut Hormones
1.5.1 Neuropeptide Y Family
Neuropeptide Y family of peptides are potent orexigenic hormones. The family consists
of  three  hormones,  Neuropeptide  Y  (NPY),  Peptide  YY  (PYY)  and  Pancreatic
Polypeptide (PP) and were first identified in 1975 [127]–[129].   In humans there are at
least four functional Y receptors (Y1R, Y2R, Y4R & Y5R)  [130]. The receptors have
different binding affinities to NPY, PYY & PP. NPY preferentially binds to Y1R and
Y5R, whilst PP binds Y4R. PYY and NPY equally bind with high affinity to Y2R. Y2R
is  mainly found in the peripheral  nervous system supplying both blood vessels  and
intestine. Y4R is mainly expressed in the gastrointestinal tract, skeletal muscle, heart
and  thyroid.  It  has  been  shown to  be  involved  in  pancreatic  secretion,  gallbladder
contraction and Luteinising Hormone secretion. Y1R and Y5R are mainly located in the
CNS, but Y1R is also found in adipose tissue and smooth muscle innervation. Agonists
of  Y2R  and  Y4R  receptors  have  been  developed  and  are  currently  undergoing
investigation as potential targets for weight management drugs.  
   
Neuropeptide Y  (NPY) is a neurotransmitter and is mainly localised to the brain and the
autonomic  nervous  system.  It  is  involved  in  a  multitude  of  processes  including
regulation of feeding, blood pressure, addiction, memory and inflammation. Release of
NPY increases food intake, and the storage of energy as fat. NPY antagonists are in
early clinical trials and hope to significantly reduce food intake and suppress appetite
and thus cause weight loss.
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Pancreatic  polypeptide  is  a  36  amino  acid  sequence  peptide  involved  in  energy
homeostasis.  It  is  produced by the PP cells  (also known as F cells)  in  the islets  of
Langerhans and is a member of the neuropeptide Y hormone family. In the fasting state
levels of PP are low, but increase within minutes of being stimulated by food [131]. Its
release follows activation of the efferent vagal nerve and in particular it is sensitive to
foods with mixed nutrient composition. Thus, PP can be used as a marker for vagal
afferent  activation.  Vagal  afferent  activation  causes  hepatic  glucose  production  to
decline and increases insulin secretion. In individuals with anorexia, baseline PP levels
are chronically elevated, but are chronically suppressed in individuals that overeat. In
studies where PP is infused into healthy volunteers, it resulted in both a reduced appetite
and decreased calorie intake. Thus, it is hypothesised that PP binds to the neuropeptide
Y4 receptors  located in  the brain stem and hypothalamus  to  suppress  appetite.  The
effects of PP last around 6hours, thus helping to regulate intervals between mealtimes.
PYY is released from enteroendocrine cells  located in the gut and some specialized
hypothalamic neuronal cells in response to food intake. PYY is released as PYY1-36
which bind to Y1R, Y2R and Y5R, but then is degraded by DPP-4 to PYY 3-36 which
can still bind to Y2R. The Y2R is commonly found in the nerves supplying the gut, thus
PYY reduces  appetite  and  decreases  gastric  motility.   When  PYY binds  to  NY2
neurones in the arcuate nucleus of the hypothalamus, it acts as a competitive inhibitor to
NPY. Thus  it  removes  the  inhibitory  effect  that  NPY has  on  the  release  of  GABA
neurotransmitters in the hypothalamic Proopiomelanocortin (POMC) neurones. In turn
this  release  of  GABA  neurotransmitters  stimulates  alpha  Melanocyte  Stimulating
Hormone (αMSH) production which is has a potent inhibitory effect on appetite [132]. 
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1.5.2 Somatostatin 
Somatostatin  secreting  cells  are  found  in  the  stomach,  pancreas  (delta  cells),
hypothalamus and intestine. Somatostatin acts on at least 5 distinct g-protein coupled
somatostatin receptors (SSTR1-5). Somatostatin primarily acts in an inhibitory capacity
on other endocrine cells and can inhibit the secretion of insulin, glucagon, GLP-1, GIP,
VIP,  Cholecystokinin,  Motilin,  Gastrin,  Secretin,  Thyroid  Stimulating  Hormone,
Growth  Hormone  and  the  exocrine  pancreatic  enzymes.  Somatostatin  release  is
sensitive to glucose concentrations, with a sudden rise in glucose resulting in a pulsatile
release of somatostatin, as well as glucagon and insulin from the Islets of Langerhams.
Somatostatin secreting cells do not appear to be affected by type 1 diabetes. However, in
pre-pubertal  individuals  they  can  maintain  a  pleuripotent  ability  and  transform
themselves into beta cells [133]. The role and interest in somatostatin as a potential drug
target has increased due to both its ability to regulate glucagon and insulin, as well as
being a potential reservoir for beta cell regeneration. In preliminary animal studies, the
inhibition of insulin has been shown to occur via the SSTR5 and inhibition of glucagon
via SSTR2 [134]. There are currently a number of SSTR2 antagonists in early phases of
development that manipulate glucagon secretion which may help to prevent recurrent
hypoglycaemia in individuals with diabetes [135] .  
1.5.3 Incretin Hormones 
Incretin describes a group of gut peptides which are released on oral food consumption
and enhance  insulin secretion that would otherwise be absent with matched intravenous
infusion. They therefore promote the efficient uptake and storage of energy. GLP-1 is a
member of the incretin family and is produced as Proglucagon which is cleaved by PC-
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1/3  in  intestinal  L-cells  to  produce  GLP-1  and  GLP-2.  Active  GLP-1  (7-36)  rises
acutely  in  response to  food consumption  (in  particular  fatty  acids  and glucose).  Its
release potentiates  insulin  release and is  estimated to  account for up to 50% of the
postprandial stimulated insulin secretion. It also appears to inhibit glucagon secretion
via a somatostatin dependent paracrine effect, thus further increasing insulin sensitivity.
Unfortunately,  it  has  a  very  short  half  life  and  is  quickly  degraded  by  Dipeptidyl
peptidase-4  (DPP-4),  so  less  than  10% of  the  total  secreted  from intestinal  L-cells
actually reaches the circulation. However, with the advent of GLP-1 agonists, it  has
been shown that it has a mechanism of action beyond its effect on insulin secretion.
GLP-1 agonists also decrease glucagon secretion, delay gastric emptying, improve non-
alcoholic fatty liver disease and reduce appetite. 
There may also be a role for GLP-1 agonists  in cardiovascular protection in type 2
diabetes, but this still remains controversial. In the “Evaluation of Lixisenatide in Acute
Coronary Syndrome” (ELIXA) trial there was no significant difference in major adverse
cardiovascular endpoints (MACE) in the lixisenatide arm compared to placebo arm of
the trial [136]. However, in the “Liraglutide Effect and Action in Diabetes: Evaluation
of Cardiovascular Outcome Results” (LEADER) trial there was a significantly lower
event rate in the liraglutide arm compared to the placebo arm for MACE [137].  Early
data from the Harmony series of clinical trials involving albiglutide have suggested a
small but significant increase in risk of atrial fibrillation in the albiglutide arm compared
to the placebo arm, but without a significant difference in MACE [138]. Cardiovascular
endpoint trials for dulaglutide are not due until 2019. However, there are outcome data
from three trials involving DPP-4 inhibitors whose mechanism of action is to increase
circulating  levels  of  GLP-1.  In  the  “Saxagliptin  Assessment  of  Vascular  Outcome
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Recorded in Patients with Diabetes Mellitus – Thrombolysis in Myocardial Infarction
S3” (SAVOR-TIMIS3) trial there was no significant difference in the saxagliptin arm
compared to  placebo arm of  the trial  for  cardiovascular  death,  non-fatal  myocardial
infarction  and  non-fatal  stroke,  but  there  was  a  significant  increase  in  hospital
admissions  for  heart  failure  [139].   In  both  the  “Examination  of  Cardiovascular
Outcomes  with  Alogliptin  vs  Standard  of  Care”  (EXAMINE)  trial  and  the  “Trial
Evaluating  Cardiovascular  Outcomes  with  Sitagliptin”  (TECOS)  there  were  no
significant differences in MACE outcomes compared to placebo  [140], [141].  Thus
suggesting  that  whilst  there  is  no  cardiovascular  protective  advantage  from DPP-4
inhibitor  drugs,  there  may  be  an  advantage  of  certain  GLP-1  agonists  in  terms  of
cardiovascular protection.  It is unlikely that we will know whether GLP-1 agonists as a
class provide a clinically meaningful level of cardiovascular protection until a complete
meta-analysis of all trials is performed. 
GIP is also a member of the incretin family of peptides and is produced from the K cells
in the small intestine [55]. It is also degraded rapidly by DPP-4 and potentiates insulin
release following oral consumption of food. GIP is typically described as a stimulant of
insulin secretion that works in a glucose dependent manner. Glucose can potentiate its
effect  on  GIP signalling  through stimulating  GIP receptor  expression  and inhibiting
DPP-4 expression. This mechanism is mainly lost in individuals suffering from type 2
diabetes through the development of GIP resistance. GIP has been shown to stimulate
glucagon secretion, which is in sharp contrast to GLP-1. Thus, there is a potential for
GIP to actually worsen glycaemic control. GIP has also been proposed to have wider
actions on adipocytes to stimulate fatty acid metabolism, osteoclastic activity to reduce
bone re-absorption and in the adrenal secretion of cortisol.    
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1.5.4 Ghrelin
Ghrelin is  a  28 amino acid peptide secreted in  the gastrointestinal  tract  and central
nervous  system  [142].  It  is  involved  in  energy  homeostasis  and  is  known  as  an
orexigenic  hormone.  Enteroendocrine  cells  in  the  stomach  and  duodenum  are  the
principle sources of ghrelin secretion.  The consumption of food stretches the gastric
lining  which  inhibits  ghrelin  section,  whilst  an  empty  stomach  stimulates  ghrelin
secretion.  Preproghrelin  is  cleaved  by  the  enteroendocrine  cells  by  prohormone
convertases  1/3  to  form  proghrelin  and  obestatin.  Proghrelin  is  then  catalysed  by
ghrelin-O-acyltransferase (GOAT) to the principal active hormone “acylated ghrelin”.
The preproghrelin gene is able to produce three distinctly biologically active hormones:
acylated ghrelin, desacylated ghrelin and obestatin.  An increase in ghrelin stimulates
the central nervous system to increase appetite and consumption of food. It decreases
under physiologically stressful conditions (e.g. infection, trauma and physical exertion)
and  on intravenous  administration  of  either  somatostatin  (SST2 specific)  agonist  or
GLP-1  or  insulin.  The  ghrelin  receptor  (GRLN-R)  in  humans  is  localised  in  the
pituitary, adipose tissue, adrenal gland, pancreas and brain [143].
1.5.5 Leptin
Leptin is  a 167 amino acid peptide which shares similar  chemical characteristics to
cytokines.  It is mainly secreted from adipocytes in white fat, but can also be produced
from the placenta, bone marrow and ovaries. Leptin levels are closely correlated to total
adipose mass  [144]. Leptin levels follow a circadian rhythm with their peak levels at
midnight  and lowest at  midday.  This is  notably opposite to  the circadian rhythm of
cortisol. Circulating leptin primarily stimulates hypothalamic neurones to inhibit hunger
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through inhibiting NPY and Agouti related peptide (AgRP) neurones and activating Pro-
opiomelanocortin (POMC) neurones. Mice that are leptin deficient (ob/ob) demonstrate
obesity, hyperphagia, increased susceptibility to infections, postural hypotension, partial
hypothalamic failure (growth hormone deficient, hypothyroid and hypogonadism) and
features of the metabolic syndrome. Mice that carry a leptin receptor mutation (db/db)
similarly demonstrate obesity,  hyperphagia,  but develop type 2 diabetes with fasting
hyperglycemia  and hyperinsulinemia.  The ob/ob mice  models  along with  the  leptin
resistant  (db/db) mice models have been crucial  in  furthering the understand of  the
physiological role of leptin and its role in insulin resistance.
In humans, congenital leptin deficiency is a rare cause of childhood morbid obesity that
can be treated with subcutaneous injections of leptin analogues. These leptin analogues
have also been shown to be effective at partially restoring hypothalamic function and
reducing features of the metabolic syndrome in both obese individuals and those with
very low body fat (eg lipodystrophy). Animal models have suggested that exogenous
leptin administration may also be an effective treatment in type 1 diabetes  [145]. The
mechanism of action was originally thought to involve the suppression of glucagon, but
this has now been refuted. Therefore, it is hypothesized that leptin restores euglycaemia
in type 1 diabetes through altering lipolysis [146].   
Outside of the field of glucose homeostasis, leptin has been demonstrated to influence
inflammation,  vascular  constriction  and  the  reproductive  system.  The  Ob-R  leptin
receptor is  found on leucocytes and shares structural similarities to class 1 cytokine
receptors, such as Il-6R and granulocyte colony-stimulating factor [147]. Activation of
this  leptin  receptor  enhances  leucocytic  phagocytosis,  stimulates  CD8+  and  B
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lymphocyte  cell  proliferation.  Thus,  leptin  could  be  considered  a  pro  inflammatory
cytokine. Animal and human models have demonstrated the presence of raised leptin
levels in auto-immune conditions such as psoriasis, rheumatoid arthritis, systemic lupus
erythematosus and inflammatory bowel disease. This tendency to develop autoimmune
disease is found to be significantly reduced in both the ob/ob and db/db mice models.
Leptins have also been shown to activate neuronal pathways in the hypothalamus that
stimulate the sympathetic nervous system  [148].  This was demonstrated through the
infusion of leptin into rodent models leading to both an increase in blood pressure and
heart  rate  [149].  The  administration  of  drugs  that  blocked  the  sympathetic  nervous
system reversed the effect. Leptin also stimulates endothelin-1 secretion in the smooth
muscle of blood vessels leading to vasoconstriction and release of oxygen free radicals
which leads to the progression of atherosclerosis  [150]. This helps to explain why the
chronic  hyperleptinaemic  state  is  associated  with  the  early  onset  of  cardiovascular
disease. Leptin is also hypothesised to effect uterine smooth muscle and research into
this field may help advance the understanding of pre-eclampsia. 
Finally,  leptin  has  been  shown to  influence  the  human  reproductive  system and  in
particular the onset of puberty. Precocious puberty is the premature onset of secondary
sexual characteristics in children and is commonly associated with the hyperleptinaemic
state of obesity. The role of the arcuate nucleus in the hypothalamus appears to be the
key  to  the  signalling  pathway  that  links  leptin  and  the  release  of  early  spike  in
gonadatrophins. Within the arcuate nucleus both the signalling pathways of “αMSH-
kisspeptin-Gonadotropin-releasing  hormone”  and  the  “leptin-αMSH”  co-exist.  It  is
hypothesized that these two pathways are to some way linked to form a “leptin-αMSH–
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kisspeptin-Gonadotropin-releasing hormone” pathway which could lead to precocious
puberty. 
    
1.5.6 Adiponectin
Adiponectin is a 224 amino acid collagen like protein that is derived from adipocytes. It
has  anti-inflammatory  and  insulin  sensitizing  properties  [151].  Compared  to  most
adipocyte derived hormones, adiponectin is inversely proportional to body mass index
with low levels recorded in obesity. It is able to suppress hepatic gluconeogenesis and
stimulates fatty acid oxidation in the liver.  There are two distinct adiponectin receptors
AdipoR1  and  AdipoR2.  AdipoR1  is  predominantly  located  in  skeletal  muscle  and
AdipoR2 is predominately located in the liver [152].  Adiponectin also been shown to
be secreted by the placenta, and levels are lower in non-pregnant females than males.
Adiponectin concentrations have also been found to be higher in males than in females.
High  levels  of  adiponectin  increase  glucose  uptake,  decreases  gluconeogenesis  and
triglyceride  clearance.  It  is  noted  that  in  non-alcoholic  steatohepatitis  (NASH)  the
expression of both receptors is reduced. In individuals with insulin resistance the levels
of adiponectin are significantly reduced. It is also used as biomarker of inflammation
and endothelial dysfunction [153]. However, in a recent meta-analysis it was not found
to be strongly linked to cardiovascular disease [154], [155]. Low levels of adiponectin
are also associated with dyslipidaemia, through modulating lipoprotein lipase activity. 
1.5.7 Il-6
Il-6 is a cytokine mainly produced from adipose tissue, but is also released from skeletal
muscle in response to acute exercise. Il-6 acts both as a pro-inflammtoary cytokine in
macrophages  and anti-inflammatory myokine through inhibiting TNF alpha and Il-1
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[115]. IL-6 levels are found to be chronically raised in obese subjects and those with
type 2 diabetes  [74]. Post exercise, Il-6 release leads to increased secretion of GLP-1
from intestinal  L-cells  and pancreatic  alpha  cells,  thus  improving  insulin  resistance
[156]. Il-6 also inhibits alpha cell apoptosis and its proliferation. Il-6 appears to have
adaptive mechanisms that are overall beneficial in individuals with type 2 diabetes.   
1.6 Clinical Characteristics of Diabetes
Diabetes  mellitus  describes  a  common clinical  characteristic  that  is  an  endpoint  of
multiple  aetiologies.  Diabetes  is  characterised  by  hyperglycaemia  along  with  the
classical  clinical  triad  of  symptoms:  polydipsia,  polyuria  and  weight  loss.  These
classical clinical symptoms can occur to a varying degree depending on the aetiology
and  the  degree  of  hyperglycaemia.  Diagnostic  criteria  for  Diabetes  were  not
standardised  until  1965  when  the  WHO produced  their  Expert  Committee  findings
[157]. This was later consolidated and simplified in the WHO second Expert Committee
report in 1980, to allow for the absence of symptoms in the diagnosis of diabetes [158].
In  the  absence  of  symptoms  then  two  separate  biological  samples  that  confirm
hyperglycaemia (fasting glucose ≥7.0mmol/l, or two-hour OGTT glucose ≥ 11.1mmol/l,
or  random  glucose  ≥11.1mmol/l  or  HbA1c  ≥  6.5%)  are  required  to  confirm  the
diagnosis.  
   
Type 1 diabetes commonly presents with acute onset of the classical clinical triad of
symptoms alongside hyperglycaemia.  However,  biochemical features may have been
present for many years before the onset of symptoms. The loss of the first phase insulin
response  occurs  prior  to  the  onset  of  symptoms  leading  to  an  increase  in  glucose
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variability [159].  
1.6.1 Type 1 Diabetes Pathology
Type 1 diabetes is histo-pathologically characterised by the lymphocytic infiltration of
the Islets of Langerhans [160]. Type 1 diabetes is a chronic autoimmune disorder with
the onset of clinical features dependent on the degree of insulin insufficiency caused by
the percentage of beta cell dysfunction and also related to the duration of dysfunction,
percentage of islets affected and rate of beta cell destruction.   Histological analysis of
pancreases from individuals newly diagnosed with type 1 diabetes show specific loss of
insulin expressing beta cells but preservation of other islets with occasionaly mild alpha
cell hyperplasia [161], [162]. Pancreatic atrophy then develops as the process continues
and is  even seen  as  early  as  symptom onset.  Atrophy progresses  over  time so  that
individuals  with  long  standing  diabetes  have  a  pancreas  which  is  frequently  50%
smaller  than  normal.  It  is  speculated  that  the  atrophy  results  from the  autoimmune
process spilling over and damaging the acinar cells that surround the inflamed Islets
[163], [164].  
1.6.2 Histopathology
Insulinitis  is  described  microscopically  as  the  infiltration  of  pro-inflammatory  cells
(cytotoxic T cells, T and B lymphocytes and macrohpages) into Islets of Langerhans
that contain beta cells. The degree of infiltration correlates to earlier age of onset of type
1  diabetes  and  presence  of  multiple  monoclonal  antibodies  targeting  islet  related
antigens.   The  target  antigens  that  have  been  identified  include:   insulin,  tyrosine
phosphatase-like protein (IA-2), islet specific glucose-6-phosphatase catalytic subunit
related protein (IGRP), preproinsulin, glutamic acid decarboxylase (GAD65) and islet
27
amyloid  polypeptide  precursor  protein  (ppIAPP)  [165],  [166].  Thus,  the  more
aggressive disease occurs in the pre-pubertal population with many of these antigens
targeted. Inflammation is more commonly seen in individuals with recent onset of type
1 diabetes, but may be present prior to symptom onset. The degree of infiltration varies
between each individual Islet and may be absent from the majority of islets in older
individuals with less aggressive inflammatory responses. 
1.6.3 Genetic and environmental susceptibility
The genetic susceptibility of developing type 1 diabetes was first demonstrated through
the use of  twin studies in 1972 [167], [168]. Further studies demonstrated that if one
mono-zygotic twin has type 1 diabetes the incidence of developing type 1 diabetes in
the  other  twin  is  approximately  40%  and  in  di-zygotic  twins  the  incidence  is
approximately 20%. However, in the background population it is only 0.2%. Genetic
susceptibility  involves  multiple  genes  primarily  involving  the  HLA class  of  genes.
Genome-wide association studies (GWAS) in the last decade have helped to identify
numerous single nucleotide polymorphisms (SNPs)  linked to  type 1 diabetes.  These
SNPs can either increase or decrease an individual's susceptibility to type 1 diabetes. In
particular the DR3/4-DQ8 haplotype (DR3=DRB1*03-DQB1*0201, DR4=DRB1*04-
DQB1*0302,  DQ8=DQA1*0301,  DQB1*0302)  occurs  in  >20% of  individuals  with
type 1 diabetes  [169], [170]. If these SNPs  are found in a newborn, then they have
approximately  20%  chance  of  developing  islet  antibodies  by  the  age  of  2  years
compared to a 2.7% background rate, which could lead on to type 1 diabetes.
Individuals who develop type 1 diabetes are thought to have a genetic susceptibility,
which  is  then  triggered  by  environmental  factors  [3].   Environmental  agents  that
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precipitate  type  1  diabetes  are  thought  most  likely  to  enter  the  body  via  the
gastrointestinal tract triggering the mucosal immune system. Environmental agents that
have been put forward as possible triggers include enterovirus, gut bacteria, cows milk
or wheat. Whilst these agents are suspected, causation for all these triggers has not yet
been proven.    
1.6.4 Current Treatments of Type 1 Diabetes
The primary treatment of type 1 diabetes is exogenous insulin administration. The goal
is to relieve symptoms, reduce hyperglycaemia, reduce glucose variability and so reduce
the risks of complications (e.g. nephropathy, neuropathy, retinopathy, hypoglycaemia
and atherosclerotic disease). In order to reduce glucose variability, exogenous insulins
and their  administrative devices have been designed to mimic a normal endogenous
response.  The  ability  to  produce  human  analogue  insulins  has  decreased  the
requirements of pancreas extract from pigs and cows. The ability to alter the speed of
insulin absorption has provided us with two main classes of insulin; the rapid acting
insulin to treat postprandial hyperglycaemia and the long acting insulin that provides a
continuous  low  level  background  dose  of  insulin.  Insulin  delivery  devices  such  as
disposable dose adjustable insulin pens has improved accuracy of insulin dose delivery.
In  particular,  continuous  subcutaneous  insulin  infusions  (CSII)  devices  that  are
programmable have made a great impact. They help to reduce glucose variability by
permitting the user to program hourly variations in their background insulin rate and
make temporary changes to their infusion rate depending on their need. 
Individuals with type 1 diabetes can now better monitor their glucose levels through
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pocket sized glucometers and the newer continuous blood glucose monitors. The ability
to easily monitor capillary glucose in response to diet and exercise provides important
biofeedback to the individual. The individual can then appropriately adjust rapid acting
insulin doses to decrease glucose variability in response to diet and exercise.  These
devices now incorporate mini computers that can calculate insulin dosage bolus advice
once pre-programmed with coefficients for diet and insulin sensitivity. In the most up to
date devices this can then be transmitted to a CSII using short range wireless technology
(e.g. bluetooth).
For  those  individuals  that  do  not  reduce  their  rate  of  hypoglycaemia  through  these
devices, then continuous glucose monitoring devices can be provided. These help the
individual to monitor their glucose variability more frequently and can be linked to CSII
devices  to  make  necessary  changes  to  their  insulin  administration.  For  those  few
individuals that continue to suffer from recurrent disabling hypoglycaemia, islet cell or
whole  pancreatic  transplantations  can  sought,  when  available,  to  relieve  symptoms
[171]–[173].         
 
Patient education is another key cornerstone of treatment for individuals with type 1
diabetes. The internationally recognised DAFNE (dose adjustment for normal eating)
course  has  provided structure  and content  to  facilitate  optimum use  of  rapid  acting
insulin and glucometers [174]. The DAFNE course and similar education courses have
been shown to significantly improve an individual's quality of life as well as improve
glycaemic control [175]. 
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1.6.5 Future Immuno-modulation treatments
Since the 1980's clinical trials have explored the theory of preserving beta cell function
through suppressing the immune system in type 1 diabetes  [176], [177]. These trials
involved immunosupressive therapy more commonly seen in organ transplant recipients
to prevent acute rejection, but unfortunately showed mixed results. Currently there are
many  therapeutic  interventions  being  investigated  to  both  prevent  and  inhibit  the
inflammatory response seen with the onset of type 1 diabetes and insulinitis. The anti-
CD3 monoclonal antibody, teplizumab, was the first new agent with preliminary data
showing significantly reduced inflammation, delay in the progression of type 1 diabetes
and  preservation  of  beta  cell  function  [178].  The  fusion  molecule  CTLA4-Ig
(Abatacept), has also been shown in early phases of research to significantly delay the
progression of type 1 diabetes by preventing the antigen presenting cells from activating
T-cells [179]. Both these drugs focus on reducing the inflammatory process of insulinitis
to delay the progressive loss of insulin secretion. An alternative immuno-modulating
approach is to identify individuals at risk of type 1 diabetes, and repeatedly present a
self-antigen to maintain immunological tolerance. Trials using repeated doses of oral
insulin in individuals that have developed the insulin antibodies (IAA) are under way
with preliminary data suggesting a delay of onset and progression of type 1 diabetes
[180].  
1.7 Type 2 Diabetes
Diabetes mellitus type 2 is less likely to present acutely than type 1 diabetes and is very
rarely associated with ketoacidosis. However, similar to type 1 diabetes, there is a pre-
diabetic period in which glucose variability increases prior to the onset of symptoms.
This  can  manifest  itself  as  an  impaired  fasting  glucose  (IFG)  or  impaired  glucose
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tolerance (IGT). In type 2 diabetes there is also a homoeostatic imbalance between the
availability of excess glucose and its utilisation.  However,  unlike in type 1 diabetes
where there is a decrease in insulin production, in type 2 diabetes it is usually due to an
increase in insulin resistance. The excess availability of glucose is usually due to  either
overconsumption of carbohydrates or excessive release of carbohydrates from glycogen
stores in the liver and muscle. The reduced utilisation of glucose is due to increased
sedentary  behaviour  and it  is  the  resistance  to  insulin  that  reduces  the  synthesis  of
glycogen. Pharmacological treatment of type 2 diabetes is principally targeted towards
reducing  and  overcoming  insulin  resistance  to  facilitate  storage  of  excess  glucose.
Significant weight loss through lifestyle changes or bariatric surgery can help to reduce
insulin resistance and can lead to remission of type 2 diabetes. There are a variety of
drugs which target insulin resistance that are used in the treatment of type 2 diabetes
including  biguanides,  peroxisome  proliferator-activated  receptor  gamma  (PPAR-γ),
DPP-4 inhibitors  and GLP-1 agonists.  Other drugs target  the availability  of glucose
through either decreasing its absorption or by stimulating glucose excretion e.g. SGLT2
inhibitors,  intestinal  alpha  glucosidase  inhibitors  and  intestinal  lipase  inhibitors.  If
insulin  resistance cannot  be reduced,  then it  can be overcome by exogenous insulin
administration.  
1.8 Other types of Diabetes
Non type 1, non type 2 diabetes encompasses a spectrum of less prevalent aetiological
causes  of diabetes,  including gestation induced,  genetic  abnormalities,  non beta  cell
endocrine disorders,  exocrine disorders of the pancreas,  infections and drug induced
diabetes. 
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Gestational  diabetes  occurs  commonly during  the second trimester  due to  hormonal
changes (e.g. cortisol, progesterone, oestradiol and human placental lactogen levels) that
increase insulin resistance. GLUT1 receptors on the placenta facilitate the transfer of
maternal glucose to the fetus. Increasing maternal glucose levels increases fetal glucose
levels which are then utilised by the fetus and stored as adipose tissue which can result
in a macrosomic baby. 
Genetic  abnormalities  leading  to  diabetes  are  numerous,  but  the  most  common
occurring abnormalities are found in a group called 'Maturity Onset Diabetes of the
Young' (MODY). MODY is a group of autosomal dominant monogenetic abnormalities
that disrupt insulin secretion. They can present with hyperglycaemia at any age, but only
occur  in  1%  of  all  individuals  with  diabetes.  Usually  they  are  initially  diagnosed
following  a  strong  family  history  of  phenotypically  similar  diabetes.  They  do  not
typically display insulin resistance or have detectable anti-islet cell antibodies. All forms
of MODY that exhibit  hyperglycaemia,  except for MODY 3 and Neonatal  Diabetes
Mellitus,  will  eventually  require  insulin  therapy.   However,  MODY 3 and Neonatal
Diabetes Mellitus tend to initially be responsive to sulfonylureas. 
1.9 Summary    
Type 1 diabetes is a chronic autoimmune disease with long term micro-vascular and
macro-vascular  sequelae  caused  by  hyperglycaemia  and  glycaemic  variability.  A
functioning network of hormones is key to glycaemic homeostasis. In individuals with
type 1 diabetes, beta cell function is impaired and there is evidence that this disrupts the
network  of  hormones.  Pancreatic  endocrine  cells  appear  to  sit  in  the  centre  of  a
hormonal  network  regulating  storage  and  utilisation  of  carbohydrates.  Determining
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which other  hormones  in  this  network  are  disrupted  could  prove  effective  as  novel
targets for new drugs. If alpha cell function did decline this may have a knock on effect
on the other hormones in the endocrine network such as GIP, GLP-1, Peptide YY, PP,
Leptin and Ghrelin.
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1.10 HYPOTHESIS AND AIMS  
Hypothesis:
• Gut Hormones are affected by type 1 diabetes
Aims:
• Establish  a  clinical  research  network  for  the  recruitment  and  study  of  gut
hormones in type 1 diabetes
• Explore the networks of gut hormones in individuals with type 1 diabetes.
• Explore  the  effects  of  lifestyle  on  the  networks  of  gut  hormones  in  type  1
diabetes.
• Explore the histopathological effect of type 1 diabetes on glucagon secreting
cells in the pancreas.
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2.  ESTABLISH A CLINICAL RESEARCH NETWORK FOR THE RECRUITMENT  
AND STUDY OF GUT HORMONES IN TYPE 1 DIABETES.  
2.1 Introduction
To  study  human  gut  hormones  it  was  important  to  establish  a  network  of  clinical
research studies in order to recruit participants. This was achieved by developing links
to an established study and by designing a new study. The priority was not only to gain
access to samples, but to ensure these samples were both in the fasting and fed state, in
a reproducible manner, as gut hormone levels vary between the two states. Thus, all
studies in the network ensured participants undertook a fast followed by a standardised
meal  stimulated  test.  To  calculate  an  appropriate  sample  size  to  ensure  statistical
significance, a search of published literature was undertaken. Unfortunately, there was a
paucity of data available that made determining an appropriate sample size impossible.
So, in order to detect a significant difference in gut peptides in type 1 diabetes compared
to healthy volunteers, it was decided to attempt to recruit at least twelve participants
with a) early onset type 1 diabetes, b) chronic type 1 diabetes and c) healthy volunteers.
2.2 Exercise in Type One Diabetes Study (ExTOD)
In order to establish a network of clinical research studies, the study coordinator of a
recently set up lifestyle intervention study was approached. The 'Exercise in Type One
Diabetes (ExTOD)' study  was recruiting individuals with new onset type 1 diabetes at
the  University  of  Birmingham.  The chief  investigator  and study coordinator  of  this
study kindly agreed to adapt the study's protocol in order to allow access to samples
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from participants undergoing meal stimulated tests. This provided a means to facilitate
the collection of samples for future measurement of gut hormone levels in individuals
with new onset type 1 diabetes. As part of the collaboration I agreed to facilitate the set
up of a second wave of study sites wishing to recruit to the ExTOD study. The study had
initially begun recruiting in November 2011 with 5 centres: United Bristol Healthcare
NHS Trust, Taunton and Somerset NHS Trust, North Bristol NHS Trust, Gloucestershire
Hospitals  NHS Trust  and University  Hospitals  Birmingham Foundation  NHS Trust.
The study  sites  involved  in  the  second  wave  that  I  was  involved  in  setting  up
commenced recruiting between October 2012 – February 2013 and included: East &
North  Herts  NHS  Trust,  Oxford  University  Hospitals  NHS  Trust,  Mid  Yorkshire
Hospitals  NHS  Trust,  Royal  United  Hospital  Bath  NHS  Trust  and  Yeovil  District
Hospital NHS Foundation Trust. The process that I undertook involved: 1) screening the
site, 2) setting up the site and 3) initiating the site.   
1. The screening process started with the identification of a site and a principal
investigator.  The  site  was  then  screened  to  ensure  the  appropriate  staff  and
equipment were in place to run the study. 
2. Setting up the site involved gaining study site approval from local research and
development departments and coordinating the signing of contracts by the Study
Sponsor and the representatives of the study site. 
3. Initiation of the site then followed after approval by both the sponsor and local
Research  and  Development  department.  This  was  the  final  practical  process
required before the site could commence the study. For the ExTOD study this
involved  identifying  a  provider  to  educate  the  local  research  staff  on
motivational  interviewing,  show them how to  use  the  activity  monitors,  and
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finally talk through the study visits.
  
2.2.1 Protocol outline for the  'Exercise in Type One Diabetes study (ExTOD)'
The Exercise in Type One Diabetes (ExTOD) Study (www.birmingham.ac.uk/extod) has
three main aims:
1. To  determine  whether  motivation  interviewing  can  increase  the  amount  of
exercise taken by an individual with newly diagnosed type 1 diabetes. 
2. To act  as  a  pilot  study to  determine  whether  an  increase  in  the  quantity  of
exercise  an  individual  with  newly  diagnosed type  1  diabetes  undertakes  can
reduce the rate of decline in c-peptide.
3. To provide feasibility data for an extended study by measuring: the enrolment
period, site count, patient recruitment rate, screen failures, drop out rates and
completion rates. 
The “Exercise in Type One Diabetes study (ExTOD)” was funded by a “Research for
Patient  Benefit”  grant  from the National  Institute  of Health Research and supported
through the Birmingham & Black Country Comprehensive Local Research Network
(UKCRN ID: 12984). The chief investigator was Dr Parth Narendran and the University
of Birmingham acted as the sponsor (ref: RG_09-123). Ethics approval was granted by
the Birmingham, East, North & Solihull research ethics committee in February 2010
(ref: 10/H1206/4).  University Hospitals Birmingham Foundation NHS Trust - Research
and Development department approved the study in March 2010 (ref: RRK3950). The
ethics  committee  submissions,   NHS  R&D  submissions,  study  protocol,   standard
operating protocols and all documentation associated with the study was authored by Dr
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Parth Narendran and Dr Amy Kennedy.
Screening for the study commenced in early November 2011 with the first participant
recruited to the study in mid November 2011. 
Study inclusion criteria:
1. Individuals  between  16-60  years  old  and  within  twelve  weeks  of  a  clinical
diagnosis of type 1 diabetes.
2. Individuals  able  and  willing  to  self-monitor  blood  glucose  and  record  their
results.
3. Individuals who are considered safe to exercise.
4. Individuals willing and able to take multiple dose injection insulin. 
5. Individuals able to increase their current exercise levels.
Study exclusion criteria:
1. Individuals who are pregnant or planning a pregnancy within the time frame of
the study.
2. Individuals with a blood pressure greater than 180/100 mm Hg.
3. Individuals taking medication that affects heart rate (e.g. beta blocker, calcium
channel antagonist, etc.)
4. Individuals with either ischaemic heart disease or psychiatric or physical disease
that would prevent exercise.
5. Individuals who are due to undergo major surgery which would prevent exercise
for more than 6 weeks within the time frame of the study. 
6. Individuals participating in another type 1 diabetes related clinical trial.
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Following recruitment (Visit 1) into the study, participants were questioned about their
medical history, underwent anthropometric measurements, and asked to wear an activity
monitor. The study involved a total of 12 study visits in the control group and 17 in the
intervention (motivational interviewing) group: 
• 1 enrolment visit 
• 1 visit (baseline) review by a dietician.   
• 3 visits (baseline, 6 months & 12 month) involved meal stimulated test.
• 3 visits (baseline, 6 months & 12 month) involved exercise fitness test.
• 4 visits (3 between baseline-6 months, 1 between 6-12months) involved clinical
assessment by diabetes specialist nurse
• Intervention group -  5 extra visits (3 between baseline-6 months, 2 between 6-
12months) involved motivational interviewing by a trained specialist nurse. 
All  participants  recruited  in  Birmingham  underwent  the  meal  stimulated  test  and
exercise  fitness  test  at  the  Wellcome Trust  Clinical  Research  Facility  at  the  Queen
Elizabeth Hospital Birmingham. 
2.3 Chronic Disease Research into Diabetes study
As  the  Exercise  in  Type  One  Diabetes  (ExTOD)  study  only  provided  access  to
individuals with newly diagnosed type 1 diabetes, an alternative study was required to
recruit patients with long standing type 1 diabetes.  A research grant from Novo nordisk
to develop a biological repository of individuals with chronic diabetes facilitated the set
up of the 'Chronic Disease Research into Diabetes' study. Unlike other repositories, this
study would have matched anthropometric data, data from validated questionnaires and
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biological  samples  on  participants  with  diabetes.  The  combination  would  provide
researchers  with  a  powerful  resource  to  screen  for  biomarkers  of  disease  and  gain
insight into the chronic disease burden of diabetes. 
The study ethics submission,  protocol,  participant documents and standard operating
protocols were all written by Dr David Hughes (author of this thesis). The application
for comprehensive research network portfolio adoption was initiated and promoted by
myself. Once portfolio adoption was gained an application to utilise the Wellcome Trust
Research Facility was submitted by Dr David Hughes and subsequently granted. Thus
facilitating  access  to  research  staff  to  aid  in  recruiting  and  processing  participants
samples. However, during the initial year of the study most participants were recruited
by Dr David Hughes (author of this thesis). 
In order to facilitate gut hormone sample collection a substantial protocol amendment
was submitted. In essence this amendment established a sub-study within the Chronic
Disease Research into Diabetes study. The two key objectives of the sub-study were: 1)
to  facilitate  the  use  of  meal  stimulated  tests  on  study  participants  to  measure  gut
hormone levels, 2) to enable the recruitment of a group of healthy volunteers to undergo
meal stimulated test in order to act as a control group. Once, this amendment had been
approved, participants recruited from the Queen Elizabeth Hospital  Birmingham site
were invited to undergo the meal stimulated test. 
The process of recruiting participants into the study evolved rapidly in the first few
months after study initiation. At the start, suitable participants who were attending an
annual diabetes clinic appointment were identified and sent a letter through the post. As
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this  failed  to  generate  significant  interest  both  myself  and  another  member  of  the
research  team  attended  these  clinics  which  further  increased  recruitment.  Finally,
electronic  means  of  communication  via  electronic  newsletter,  websites  and  text
messaging were employed. This involved me developing a short email advert that was
distributed  through  the  help  of  the  communication  teams  at  the  University  of
Birmingham and Queen Elizabeth Hospital.  Then using NHS email facilities to send
patients SMS text messaged about the study as well as working with the University of
Birmingham  web  team  to  develop  a  web-page  for  the  study
(http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/primary-
care/cdr/). These methods of recruiting participants enabled me to recruit the majority of
participants to the study from the Queen Elizabeth Hospital Birmingham site.     
The study was initially set up as a single site, but subsequent amendments facilitated the
role out of the study to multiple sites in the Midlands. These amendments to the study
involved key changes and innovations that were initiated and continued by Dr David
Hughes (author of this thesis) and facilitated the expansion of the study:
1) Development of a secure website to enable electronic uploading of data and 
communication with researchers from all study sites.
2) A reduction in the study visits and initiating online follow ups.
3) Collaboration with the Birmingham & Black County Comprehensive Local
Research Network (BBC CLRN) to invest in research nurse time to support the set
up of new sites.
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2.3.1  Protocol  outline  for  the  “Chronic  Disease  Research  into  Diabetes  study”
(CDRD)  
The  “Chronic  Disease  Research  into  Diabetes  study”  (www.birmingham.ac.uk/cdr-
diabetes) is an observational study and  has two aims: 
1. To develop a repository of data and biological samples for the detection of novel
biomarkers.
2. To  investigate  the  chronic  disease  burden  of  diabetes  on  individuals  with
diabetes.
The “Chronic Disease Research into Diabetes study” was funded by a research grant
from  the  pharmaceutical  company  Novo  Nordisk  and  supported  through  the
Birmingham & Black Country Comprehensive Local Research Network (UKCRN ID:
12984).  The  chief  investigator  was  Dr  Parth  Narendran  and  the  University  of
Birmingham acted as the sponsor (ref: RG_12-061). Ethics approval was granted by the
West  Midlands  –  Staffordshire  regional  ethics  committee  on  April  2012  (ref:
12/WM/0089).  University Hospitals Birmingham Foundation NHS Trust - research and
development department approved the study in August 2012 (ref: RRK4441). The ethics
committee submissions,  NHS R&D submissions, study protocol,  standard operating
protocols and all documentation associated with the study was authored by Dr David
Hughes (author of this thesis). 
Screening for the study commenced in early September 2012 with the first participant
recruited to the study in mid September 2012. In April 2013 the study was adopted at
Russells  Hall  Hospital  (Dudley),  City  Hospital  (Birmingham),  Good  Hope  Hospital
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(Sutton Coldfield), Walsall Manor Hospital and Heartlands Hospital (Birmingham).  
Study inclusion criteria: 
1. Individuals  who  fulfilled  the  World  Health  Organisation  (WHO)  2011
classification for a diagnosis of either diabetes, or impaired fasting glucose, or
impaired glucose tolerance.
Sub-study inclusion criteria:
1. Maximum  of  24  healthy  participants  to  undergo  a  meal  stimulated  test  to
determine normal gut hormone levels.  
Major exclusion criteria included:
1. Unable to provide full informed consent.
2. Significant  illness  (including  psychological,  psychiatric,  developmental  or
physical disease) that may prevent a study visit attendance.
3. The  principal  investigators  opinion  that  participation  would  not  be  in  the
individuals best interest, due to the potential of psychological harm.
4. Participation in an intervention study.
Following enrolment into the study, participants were questioned about their medical
history, before undergoing anthropometric measurements: 
• Blood pressure and pulse were measured from the non-dominant arm. 
• Height and weight were measured. 
• Hip circumference was taken from the widest point at the level of the greater
trochanter.
• Waist  circumference  was  taken  at  the  halfway  point  between  the  greater
trochanter and xiphoid process of the sternum. 
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• Thigh circumference was taken from the non-dominant leg at the widest level of
the thigh just below the groin. 
• Neck  circumference  was  taken  during  exhalation  at  the  level  of  the  thyroid
cartilage. 
All measurements were taken by a qualified healthcare professional who had undergone
training.  After all anthropometric measurements had been completed the participants
were asked to complete a series of questionnaires (see Appendix 2) which included:
• Socio-demographic  information:  gender,  age,  ethnicity,  level  of  academic
attainment, employment status. 
• Lifestyle  information:  smoking,  alcohol  consumption  (measured  by  the
validated  questionnaire  “Alcohol  Use  Disorders  Identification  Test
Consumption” (AUDIT-C)), sedentary time and quality of life (measured by the
validated  questionnaire  “EuroQol  five  dimensions  questionnaire”  (EQ-5D))
[181], [182].
• Depression  (measured  by  the  validated  questionnaire  “Patient  Health
Questionnaire 9 point” (PHQ-9)) [183].
• Eating  behaviour   (measured  by  the  validated  questionnaire  “Three  Eating
Factors Questionnaire – 18 point” (TEFQ-18)) [184].
 
On completion of the baseline visit,  participants were asked whether they wished to
attend an optional extra visit to complete a meal stimulated test at the Wellcome Trust
Research Facility, Queen Elizabeth Hospital, Birmingham. Participants were provided
with a separate participant information sheet concerning the meal stimulated test visit
before attending this optional visit. All these meal stimulated tests were arranged and
supervised by Dr David Hughes (author of this thesis). 
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Recruitment  of  participants  at  the  Queen  Elizabeth  Hospital,  Birmingham occurred
through the distribution of the “participant information sheets” to individuals attending
a  diabetes  clinic.  Healthy  volunteers  were  recruited  through  advertising  via  the
University  of  Birmingham's  weekly  e-mail  newsletter  and  through discussions  with
healthy relatives of participants recruited to the CDRD study. Dr David Hughes (author
of  this  thesis)  distributed  the  participants  information  sheets,  organised  the  email
advertising and recruited the majority of participants into the CDRD study during 2012-
2014. Dr David Hughes (author of this thesis) also worked closely with CLRN research
staff in order for the study to continue to actively recruit participants both at Queen
Elizabeth Hospital Birmingham and later at multiple sites across the Midlands. 
2.4  Demographics  of  Participants  recruited  from  the  'ExTOD'  and  'CDRD'
studies.
The combination of both the 'Exercise in  Type One Diabetes'  and 'Chronic Disease
Research into Diabetes' facilitated the collection of samples from participants with: a)
early onset type 1 diabetes, b) chronic type 1 diabetes and c) healthy volunteers. All
samples were then stored at  -80°C in preparation for analysis.  Listed below are the
gender,  age and body mass index (BMI) of all  'ExTOD' participants whose samples
were collected and stored ready for analysis (see Table 2.1). All participants recruited
from the ExTOD study had a duration of type 1 diabetes of under one year.
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Table  2.1:  Demographics  of  participants  recruited  from  the  Exercise  in  Type  One
Diabetes Study.
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ID Gender Age
ex** Male 30 28
EX001 Female 29 24
EX002 Male 29 26
Ex003 Male 21 22
Ex004 Male 24 27
Ex005 Male 22 25
Ex006 Male 27 21
EX007 Female 24 23
EX008 Male 18 24
EX009 Male 26 28
EX011 Male 18 25
EX012 Male 22 27
EX013 Female 29 34
EX014 Male 27 28
EX016 Male 39 23
EX017 Male 38 28
EX018 Female 31 22
EX019 Male 30 23
EX020 Female 17 27
EX021 Female 26 26
EX022 Male 33 25
EX023 Male 31 29
EX025 Male 20 20
EX026 Female 22 24
EX027 Female 54 35
EX031 Female 27 18
EX032 Male 44 24
Body Mass 
Index
Listed below are the gender, age, body mass index (BMI) and duration of diabetes of all
healthy 'CDRD' participants whose samples were collected and stored ready for analysis
(see Table 2.2). 
Table  2.2:  Demographics  of  healthy  volunteers  recruited  from the  Chronic  Disease
Research into Diabetes study.
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ID Gender Age Body Mass Index
101 Male 35 26
103 Male 46 20
105 Female 63 28
106 Female 43 19
107 Female 43 25
108 Female 57 21
110 Female 48 23
111 Female 32 22
112 Male 38 20
113 Female 57 36
114 Male 26 22
115 Female 47 28
116 Male 56 26
117 Female 41 20
118 Female 28 21
122 Female 48 37
123 Female 32 27
126 Male 30 23
127 Male 71 28
128 Male 21 19
129 Male 25 25
130 Female 50 28
131 Male 76 21
134 Female 36 22
Listed below are the gender, age and body mass index (BMI) of all 'CDRD' participants
with type 1 diabetes whose samples were collected and stored ready for analysis (see
table 2.3).
  
ID Gender Age
6 37 Male 52 49
12 64 Male 76 27
13 7 Male 26 21
16 14 Male 65 27
22 5 Male 26 22
23 57 Female 57 26
27 30 Female 41 28
28 21 Female 54 32
30 22 Female 33 20
32 39 Female 58 28
34 38 Female 49 30
36 37 Male 37 26
40 39 Female 59 23
47 23 Male 62 24
49 52 Male 75 27
53 21 Male 23 28
56 31 Female 52 23
61 1 Male 18 24
62 21 Male 35 27
64 26 Female 46 31
67 19 Female 50 23
Duration of Type 
1 Diabetes
Body Mass 
Index
Table 2.3: Demographics of participants recruited from the Chronic Disease Research
into Diabetes study with type 1 diabetes.
2.5 Discussion
The success of this research hinged on the ability to recruit participants with type 1
diabetes to studies that would faciliate access to standardised samples in both the fasted
and  fed  state.  This  was  achieved  through  collaborating  with  researchers  from  the
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'ExTOD' study as well as setting up a new study 'CDRD'. The target of collecting at
least 12 participants samples from 1) healthy volunteers, 2) individuals with acute onset
type  1  diabetes  and  3)  individuals  with  chronic  type  1  diabetes  was  also  met  and
exceeded. In total 24 healthy volunteers, 28 participants with a duration of diabetes <2
years and 20 participants with a duration of type 1 diabetes >2 years were recruited and
undertook a meal stimulated test. 
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3. OPTIMISE SAMPLE COLLECTION AND ASSAYS FOR GUT HORMONE  
ANALYSIS  
3.1 Introduction
At the start of the study there was no departmental protocol for sample collection or
processing for human gut hormones. In order to develop a sample collection protocol, I
undertook  a  review  of  available  literature  to  gain  an  insight  into  assays  and  their
methods used for sample collection. The key focus was to find low cost assays that had
low concentration detection ranges for gut hormones, in particular glucagon and active-
GLP-1.  Gut  hormone  assay  instruction  manuals  from  websites  of  commercial
biotechnology companies as well as peer reviewed journal methods were included in the
search. Please see Table 3.1 for the results of the assay search and Table 3.2 for the
results of the sample collection methods.
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Kit Cost Detection Range Pro Cons
Millipore Glucagon RIA
Medium cost
None
Low cost assay
None
RayBiotech Human 
Glucagon EIA
£220 per 96 
well
Glucagon = 1-
1,000 pg/ml
Low cost assay with 
lowest glucagon 
detection range
Instructions appear 
complicated
Mercodia Glucagon 
ELISA
£525 per 96 
well plate
Glucagon = 5 – 
453 pg/mL
Very simple instructions 
with pre made standards. 
Second lowest detection 
range.
New assay. Medium 
ranged price
£300 per 250 
tubes
Glucagon = 20–
400 pg/mL
Low cost assay with 
plenty of publications.
Would need specialist 
training and no one 
currently available to 
supervise me.
Phoenix Pharmaceuticals 
Glucagon EIA kit
£400 per 96 
well plate
Glucagon = 160-
3740 pg/ml
Worst detection range 
out of glucagon assays
R&D High Sensitivity Il-6 
ELISA kit
£400 per 96 
well plate
Il-6 = 0.2 - 10 
pg/mL
Medium cost. Very low 
detection range. 
Recommended by team 
at Bristol & Warwick 
RayBiotech Active GLP-1 
£220 per 96 
well
Active GLP-1 = 
1.17 - 1,000 pg/ml
Assay protocol not 
straightforward
Millipore High Sensitivity 
GLP-1 Active ELISA Kit, 
Chemiluminescent
£400 per 96 
well plate
Active GLP-1 = 
0.46-330 pg/mL
Medium cost. Very low 
detection range
MSD Human Active GLP-
1, Insulin, Glucagon, 
Leptin Kit
£1200 per 96 
well plate
Glucagon = 21-
10000pg/ml; 
Active-GLP-1 = 
1.0-10000pg/ml; Il-
6 = 13.7-10,000 
pg/mL
Multi-analyte assay 
which is very cost 
efficient. Recommended 
assay by the team at 
Cambridge.
Company informs me 
that nearest serviced 
machine is based in 
Warwick.
Millipore MAP Human 
Metabolic Hormone 
Panel - (C-Peptide, 
Ghrelin (Active), GIP 
(Total), Leptin, PP, PYY 
(Total)
£1080 per 96 
well plate
Glucagon = 13.7-
10,000 pg/mL; 
Active GLP-1 = 
2.7-2,000 pg/mL
Multi-analyte assay 
which is very cost 
efficient. Serviced 
machine at Uni of Bham.
Would need to contribute 
to service costs of 
machine.
Table 3.1: Review of potential commercial assays with pros and cons.
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Kit Hormone Collection Method
Glucagon
Glucagon 
Active-GLP-1
Active-Ghrelin
Mercodia 
Glucagon ELISA
Method 1: Collect samples in EDTA tubes stored at room 
temperature for <2 hours Aliquot plasma and freeze at -80°C. 
Method 2: Collect samples in Becton Dickinson (BD) P800 tubes 
containing a cocktail of protease, esterase and DPP-IV Inhibitors 
stored at room temperature for <6 hours. Aliquot plasma and freeze at 
-80°C.
Millipore Glucagon 
RIA
Collect samples in EDTA tubes containing 250 KIU Aprotinin per mL 
of whole blood. Aliquot plasma and freeze at -20°C - -70°C.
Millipore MAP 
Human Metabolic 
Hormone Panel
C-Peptide, Ghrelin 
(Active), GIP 
(Total), Leptin, PP, 
PYY, Amylin, Il-6
Collect samples in EDTA tubes, then add DPPIV inhibitor, protease 
inhibitor cocktail, Aprotinin and AEBSF.
MSD Human 
Active GLP-1, 
Insulin, Glucagon, 
Leptin Kit
 Active GLP-1, 
Insulin, Glucagon, 
Leptin
Collect samples in EDTA tubes containing DPP-4 inhibitor & 500 
KIU Aprotinin per mL of whole blood. Aliquot plasma and freeze at 
-80°C
Millipore High 
Sensitivity GLP-1 
Active ELISA Kit, 
Chemiluminescent
Collect sample in EDTA tubes, immediately (<30 seconds) after 
collection add DPP-IV inhibitor.Aliquot plasma and freeze at -80°C.
Millipore Human 
Ghrelin (active) 
ELISA
Collect samples in EDTA tubes treated with Pefabloc or AEBSF. 
Then acidify plasma samples with HCl to a final
concentration of 0.05N. Aliquot plasma and freeze at -80°C.
Table 3.2: Review of collection methods from assay kits.
The  review  of  assays  and  collection  methods  highlighted  an  important  aspect
concerning freeze-thaw cycles. Performing multiple assays would increase the number
of freeze thaw cycles and thus the degradation of the gut hormone in the sample. Assays
that could be performed at the same time would help reduce the number of freeze thaw
cycles and prevent sample degradation. This meant that there was one assay that was a
clear  forerunner  as  it  was  both  low  cost  and  could  measure  multiple  analytes
simultaneously.  The 'Human Metabolic  Hormone Magnetic  Bead Panel  Luminex kit
(#HMHMAG-34K)'  provided by EMD Millipore  Corporation  (Billerica,  MA,  USA)
provided  a  means  to  assay  multiple  gut  hormones  using  luminex  multiple  analyte
profiling technology,  that  would provide a  cost  saving over  traditional  ELISAs and
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would keep freeze thaw cycles to a minimum. The kits literature described a sample
collection  method  that  was  similar  to  the  other  collection  methods.  The  collection
method  included  adding  DDP-4  inhibitors  to  prevent  degradation  of  active-GLP-1,
AEBSF to  prevent  degradation  of  actyl-ghrelin,  aprotinin  to  prevent  degradation  of
glucagon  and  protease  inhibitor  cocktail  to  prevent  degradation  of  amylin.  As  no
members of my lab had ever measured gut hormones before, I discussed this selection
with researchers from the field of gut peptides at the University of Bristol, University of
Warwick  and  University  of  Cambridge.  They  all  commented  on  the  difficulty  of
measuring glucagon and advised me to collect  a  separate  sample  containing  DPP-4
inhibitor and aprotinin for glucagon analysis in case the detection range of the Human
Metabolic  Hormone  Magnetic  Bead  Panel  Luminex  kit  was  not  good  enough.
Therefore,  I  decided  to  use  two  collection  methods  in  the  hope  that  one  sample
collection method would be good enough.   
3.2 Methods and materials for preparing gut hormone blood collection tubes
The two methods selected for preparing blood collection tubes and cryovials were given
the terms 'Tube A' and 'Tube B'. Tube A preparation instructions were taken from MSD
and Millipores sample collection methods for analysing single glucagon and active-glp-
1 hormones.  Tube B preparation instructions were taken from the sample collection
method as provided by the Human Metabolic Hormone Magnetic Bead Panel Luminex
kit (#HMHMAG-34K) with the use of a protease inhibitor cocktail containing AEBSF,
Aprotinin, Bestatin, E-64, Leupeptin, Pepstatin A . Below are the methods and materials
used to prepare these two gut hormone blood collection tubes. 
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Tube A: 2ml EDTA Vacuette tube (#454087, Greiner Bio-one GmbH, Frickenhausen,
Germany)  of  which  20  μl  DPP-4  inhibitor  (#DPP4,  EMD  Millipore  Corporation,
Billerica,  MA,  USA) and  1000 kIU Aprotinin  (#616371,  Merck KGaA,  Darmstadt,
Germany) was added.
Tube B: 2ml EDTA Vacuette tube (#454087, Greiner Bio-one GmbH, Frickenhausen,
Germany)  of  which  20  μl  DPP-4  inhibitor  (#DPP4,  EMD  Millipore  Corporation,
Billerica, MA, USA) and 20 μl of 100mM Pefabloc® SC (#76307, Sigma-Aldrich, St.
Louis, MO, USA) was added. Tube B also had an accompanying cryovial for Tube B:
1.5ml Sterile Natural Cryovial (#V4381, Sigma-Aldrich, St. Louis, MO, USA) of which
5 μl of Protease Inhibitor Cocktail (#P8340, Sigma-Aldrich, St. Louis, MO, USA) was
added to every 0.5ml serum.
As these sample collection tubes and cryovials needed to be prepared in advance, they
were stored at -20°C for up to one month. This time frame was selected as it was shorter
than the time frame given by the commercially available gut peptide collection tubes
provided by BD Bioscience (Franklin Lakes, New Jersey, U.S.A) i.e. P700 and P800
collection  tubes.  The  decision  to  prepare  my  own  collection  tubes  compared  to
purchasing these commercially available gut peptide collection tubes was based on cost
alone (own collection tubes = £3 each vs P700/P800 tubes = £12 each). 
3.3 Meal stimulated test and sampling protocol
As gut hormone levels vary with ingestion of food, it is important to use a method such
as  the  meal  stimulated  test  in  order  to  standardise  samples.  All  participants  were
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recruited from the Queen Elizabeth Hospital Birmingham for both the 'ExTOD' study
and those healthy volunteers and participants with type 1 diabetes from the 'CDRD'
study. Participants were asked to attend the Wellcome Trust Clinical Research Facility at
the Queen Elizabeth Hospital  Birmingham between 8:45 – 9:30am in a  fasted state
having consumed nothing except for plain water for 10 hours. All short/rapid acting
anti-diabetic  medication  was  omitted  prior  to  the  test.  Participants  who had a  mild
hypoglycaemic episode during the fast that required only a single dose of rapid acting
sugars (eg dextrose tablet,  lucozade, jelly babies, etc) could proceed with the test as
long  as  this  occurred  >4 hours  prior  to  the  first  blood sample.  A pre-test  capillary
glucose  reading was  taken using  the  participant's  own glucose  monitor.  If  capillary
glucose  was  <4mmol/L  then  they  were  treated  for  hypoglycaemia  and  the  test
rescheduled.  If  glucose  was  >15mmol/L  the  test  would  continue  under  medical
supervision, if the participant felt well and had not developed ketosis.  
At the start of the meal stimulated test a peripheral cannula was inserted in order to
collect multiple blood samples during the test. Blood samples were taken at time points:
-10min, 0min, 15min, 30min, 60min, 90min & 120min and kept in an ice bucket until
centrifuged. Blood samples were collected into a 4ml EDTA Vacuette tube (#454021,
Greiner Bio-one GmbH, Frickenhausen, Germany), a 2ml Fluoride Oxalate (#454061,
Greiner Bio-one GmbH, Frickenhausen, Germany), and the chilled hormone collection
tubes. Immediately after the 0min blood sample was taken, each participant was asked
to drink 240ml of standard fortisip (#18475, Nutricia Ltd, Trowbridge, UK) within the
subsequent 5 minutes. 
Blood samples were centrifuged within 45 minutes of sample collection at 1100-1300g
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at 4°C for 10 minutes. Then 0.5ml of plasma from each sample collection tube was
transferred into two cryovials. All samples were initially frozen at -20°C for up to 2
weeks before being transferred to a -80°C storage. 
After the 120min blood sample was taken, a capillary blood glucose test  was taken
before the cannula was removed. Participants were reviewed by a clinician and advised
what medication to take before being provided with a meal.
3.4 Human Metabolic Hormone Magnetic Bead Panel Luminex Assay
The Human Metabolic Hormone Magnetic Bead Panel Luminex kit (#HMHMAG-34K)
was provided by EMD Millipore Corporation, Billerica, MA, USA. The 96 microplate
was washed with assay buffer  and then  tapped dry.  Standards,  controls  and plasma
samples were added to each well of the microplate. Magnetic detection beads were re-
suspended  in  bead  diluent  before  being  added  to  each  well.  The  microplate  was
incubated  overnight  at  4°C on a  plate  shaker.  The  microplate  was  washed  using  a
magnetic plate washer (#Bio-Plex Pro Plate Washer, Bio-Rad Laboratories, Hercules,
CA, USA). Then human metabolic panel detection antibodies were added to each well
and  incubated  for  30  minutes  at  room temperature  on  a  plate  shaker.  Streptavidin-
Phycoerythrin was then added to each well, incubated for a further 30 minutes at room
temperature on a plate shaker.  Finally,  the microplate was washed using a magnetic
plate washer, before being analysed on a Bio-Plex 200 machine (Bio-Rad Laboratories,
Hercules, CA, USA). The reader was gated for each magnetic bead, set at a 50 bead
count with a 60 second time out.  
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3.5 Results comparing the two gut hormone sample collection methods
The first three pairs of samples using the two different sample collection methods were
compared  for  all  gut  hormones  in  the  panel  using  the  Human  Metabolic  Hormone
Magnetic Bead Panel Luminex kit (#HMHMAG-34K). The results for each analyte are
shown below.
Tube A Tube B
Sample A Sample B Sample C Sample A Sample B Sample C
C-peptide 10082 917 0 12424 398 47
Acetyl-Ghrelin 771 3270 318 1883 15689 3160
GIP 17049 7725 5816 13826 6778 7304
GLP-1 1939 497 115 2729 1392 773
Glucagon 3117 0 0 1823 0 0
Leptin 30142 221326 128634 29288 199625 134967
PP 20127 11713 21310 21395 15759 28825
PYY 17860 2831 0 18803 7409 1330
Il-6 0 0 0 0 0 0
Amylin 0 0 0 0 0 0
Table 3.3: Results from three participant samples comparing sample collection methods
for an array of gut hormones measured by the Human Metabolic Hormone Magnetic
Bead Panel Luminex kit reported as the Area Under the Curve for 0-120 minutes.
The results obtained show that levels of Il-6 and amylin were too low to be detected in
the samples analysed. This suggests that either there were problems with the sensitivity
of the assay used in analysing Il-6 and amylin or in the collection method. However, as
two independent collection methods had been used, it was felt that it was more likely to
be a problem with the sensitivity of the assay especially in relation to Il-6. There was
also concern regarding the sensitivity of the assay in analysing glucagon and active
GLP-1. Two of the three glucagon samples had recorded undetectable levels and the
active  GLP-1 results  were only  just  above the  manufacturers  stated  lower  limits  of
detection. Thus, it was decided to find alternative assays for detecting glucagon, active
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GLP-1, Il-6 and amylin. 
In order to determine which sample collection method had provided the greatest gut
hormone yields the combined total yields for each collection method was calculated and
the difference between the sample collection methods calculated (see table 3.4). 
Total Tube A Total Tube B % Difference
C-peptide 10999 12868 15
Acetyl-Ghrelin 4359 20732 21
GIP 30590 27908 9
GLP-1 2551 4893 52
Glucagon 3117 1823 42
Leptin 380101 363880 4
PP 53150 65979 19
PYY 20692 27542 25
Table 3.4: Total  yields  of the two sample collection methods from three participant
samples. The highest yield is in  bold.  The percentage difference is that between the
lowest and highest yield collection method. 
These results confirm that sample collection method using Tube B generated a greater
hormone yield for all hormones except for Glucagon, GIP and Leptin. The difference in
yields for leptin (4% higher yield in Tube A) and GIP (9% higher yield in Tube A) were
felt to be small enough that these hormones could still be analysed using collection tube
B. However, as the difference in yield for  glucagon was 42% higher in Tube A than
collection  Tube  B,  then  this  method  would  continue  to  be  used  for  glucagon.  The
conclusion of this analysis was that two collection methods would continue to be used
in all participants. Tube A would be used for glucagon analysis and tube B would be
used for all other gut hormone analysis.  
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3.6 Selection of alternative assays
The process of selecting an alternative assay for glucagon, amylin, Il-6 and active GLP-
1 started by reviewing the detection ranges for each available commercial assay. The
priority was to find a suitable glucagon and active GLP-1 assay as there was significant
scientific interest in alpha cell function and the incretins in type 1 diabetes. RayBiotech
glucagon assay and Mercodia AB glucagon assay were short listed following review of
available literature (see Table 3.1). The two active GLP-1 assays that were also short
listed were RayBiotech active GLP-1 assay and Millipore High Sensitivity active-GLP-
1 assay. The only short listed Il-6 assay was R&D Systems High Sensitivity Il-6 assay,
but no high sensitivity amylin assay was short listed. The UK distributor for RayBiotech
then offered a significant discount off  the list  price for both their  active-GLP-1 and
glucagon assay which made these assays significantly cheaper than their competitors.
As both the RayBiotech Glucagon and active-GLP-1 assays used the same methods then
it  was  possible  to  use  them in  tandem,  reducing  freeze-thaw  times.  Therefore,  the
RayBiotech assays were selected and samples were processed using these assays. 
3.7 Method of sample processing using RayBiotech Glucagon and GLP-1 EIA
Plasma samples from collection tube B collected during the meal stimulated test at time
points: -10min, 0min, 15min, 30min, 60min, 90min & 120min were taken out of -80°C
storage  and  allowed  to  thaw  on  a  workbench.  The  Glucagon  and  GLP-1  EIA kits
provided by RayBiotech (Norcross, Georgia, USA) were stored at -80°C until used. The
microplate in the kits were pre-coated with secondary anti-rabbit IgG antibody. When
preparing the assay then either anti-glucagon or anti-glp-1 antibodies were added to the
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microplate, incubated overnight at 4°C on a plate shaker before being washed. Plasma
samples were diluted four fold into micro-centrifuge tubes and combined with either
biotinylated-glucagon or biotinylated-GLP-1. The mixed samples were added to each
well alongside standards and controls before being incubated overnight at 4°C on the
plate shaker. During this phase the plasma glucagon or GLP-1 in each sample competes
with their respective biotinylated-peptide for the binding sites on the microplate. The
microplate was then washed and streptavidin-horseradish peroxidase (SAHRP) added to
produce a colour reaction with the biotinylated moiety that is bound to the plate. The
colour intensity of each well  was measured at  450nm absorbance on a Synergy HT
Multi-Mode  Microplate  Reader  (BioTek,  Winooski,  VT,  USA).  The  intensity  of
colorimetric signal was inversely proportional to the amount of plasma Glucagon or
GLP-1 peptide in the four fold diluted plasma samples.
3.8 Experience of using RayBiotech Glucagon and GLP-1 EIA
As samples  were  processed  it  became evident  that  whilst  the  method of  measuring
levels of glucagon and active-glp-1 with these assays was valid, it was time intensive
and prone to preparation errors. Also, there was concern that the intra-assay variability
may be greater than published. Thus the confidence in the assay was adversely affected
and concerns about reproducibility of our results led us to abandon these assays. We
therefore turned to  the more expensive Mercodia Glucagon assay and the Millipore
High  Sensitivity  active-GLP-1  assay  and  were  immediately  impressed  with  these
assays. The Mercodia glucagon assay came with both its own pre-prepared controls and
standards that reduced possible preparation errors. It was also simpler and quicker to use
than the RayBiotech assay. The Millipore High Sensitivity active-GLP-1 assay was also
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less time intensive and by coming with two prepared control samples it increased our
confidence in its results. During this process of assay optimisation both time and money
had been lost, which led us to abandon our aim of optimising an amylin and Il-6 assay. 
3.9 Method of sample processing using Mercodia Glucagon ELISA assay.
Plasma samples from collection tube A collected during the meal stimulated test at time
points: -10min, 0min, 15min, 30min, 60min, 90min & 120min were taken out of -80°C
storage and allowed to thaw on a workbench. The glucagon enzyme immunoassay was
provided by Mercodia AB, Uppsala, Sweden. The microplate in the kits were pre-coated
with  an  anti-glucagon  antibody.  Plasma  samples  and  calibration  samples  were
transferred in duplicate to wells on the microplate. Peroxidase conjugated anti-glucagon
antibody solution targeting a second binding site was then added to the each well. The
microplate was incubated for 18-22hrs at  4C on a plate shaker.  The microplate was
washed and 3,3’,5,5’-tetramethylbenzidine (TMB) solution was then added to produce a
colour reaction. The colour intensity of each well was measured at 450nm absorbance
on a Synergy HT Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA). The
intensity of colorimetric signal was proportional to the amount of plasma Glucagon in
each sample.
3.10 Method of sample processing using Millipore active GLP-1 ELISA assay
The  active  GLP-1  ELISA  (#EZGLPHS-35K)  was  provided  by  EMD  Millipore
Corporation, Billerica, MA, USA. The microplate in the kits were pre-coated with an
anti active-glp-1 antibody. The microplate was washed with buffer and then tapped dry.
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Standards,  controls  and plasma samples were added to each well  of the microplate.
GLP-1 capture antibody solution was then added to each well. The plate was incubated
for two hours at room temperature on a plate shaker. The plate was washed, before a
detection antibody was added to each well and then incubated for one hour at room
temperature on a plate shaker. The plate was washed and Enzyme Solution added to
each well before being incubated for 30 minutes at room temperature on a plate shaker.
The plate was washed and substrate solution added to each well. The microplate was
immediately  read  at  425nm on a  Centro  LB 960 microplate  luminometer  (Berthold
Technologies GmbH, Bad Wildbad, Germany).   
3.11 Discussion
The  aim  of  optimising  both  sample  collection  methods  and  assays  was  not  a
straightforward process,  but  was finally  achieved.  In  order  to  measure gut  hormone
levels,  two  sample  collection  methods  were  compared  to  find  the  method  which
provided the highest yield. The results showed the need to use both collection methods
as the yields varied depending on the gut hormone analysed. 
The initial intention to use Millipores luminex multiple analyte profiling technology to
analyse all gut hormones resulted in failure to detect levels of Il-6, amylin, glucagon and
active GLP-1 in the cohort of samples. Our second choice of assay for glucagon and
active-glp-1 analysis using RayBiotech's assays turned out to be plagued with problems
as  plates  were  repeatedly  spoiled  due  to  preparation  errors,  internal  quality  control
sample results outside of acceptable limits, and so the confidence in the reproducibility
of the results  these assays produced waned. This led us to use Mercodia's  glucagon
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assay and Millipore's high sensitivity active-GLP-1 assay. Both these assays were easy
to  prepare,  with  internal  control  samples  repeatedly  within  acceptable  limits  that
ultimately led to our confidence in their use for all our samples. Unfortunately, the time
and cost taken in optimising assays and sample collection meant that Il-6 and amylin
levels were not measured. 
On reflection, it would have been worth spending more time before sample analysis to
validate the methods of sample collection and analysis. The process of validating these
could have occurred with the help of an academic from another laboratory. The first step
would have  required  taking matched samples  of  blood from a volunteer  as  per  our
sampling methods and stored according to protocol. Reference samples of gut peptides
with known concentrations would need to be obtained, undergo serial dilution and then
split into pairs.  Half the samples (volunteer and diluted reference samples) would then
be simultaneously analysed on our selected assays at two laboratories. The results could
then  be  analysed  to  determine  within  laboratory  variations  of  the  assays  and
reproducibility of the assays between laboratories for both the reference samples and the
human samples. By repeating the simultaneous analysis at two laboratories we could
analyse  repeatability  (intra-assay  precision)  and  determine  which  collection  method
produced  the  greatest  gut  peptide  yield  as  well  as  lowest  sample  degradation.
Unfortunately, these steps were not performed due to the fact that most samples had
already been collected by the time the problem had been identified. The cost both in
time for repeating sample collection and monetary value of the assays prohibited our
ability to complete the validation process during this research project. 
The use of three assays and two collection methods was not ideal in practical terms, but
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it did lead to an increase in confidence in our results. Ideally, we would have preferred
to use one sample collection method in order to reduce preparation time and cost of
consumables. However, one of the advantages of using two methods, was the ability to
use  sample  collection  methods  that  better  matched  the  assay  manufacturers
recommended  sampling  protocols.  Another  strength  of  using  two  sample  collection
methods was that it prevented the need for repeated freeze-thaw cycles that could have
led to sample degradation. The decision to prepare our own collection tubes also had the
advantage  of  keeping  costs  down  compared  to  purchasing  commercially  available
collection tubes. This needed to be offset against the disadvantage of longer preparation
time.  
In terms of our assays, again it would have been ideal to have found one multi analyte
assay  that  could  have  accurately  measured  all  the  gut  hormones  simultaneously.
Millipore's multi-analyte assay came very close to being ideal, as it accurately measured
multiple  hormones simultaneously.  This  ability  saved both significant  time and cost
compared to using multiple individual assays making it very economically efficient. The
Millipore  multi-analyte  assay  also  had  the  advantage  of  coming  with  multiple
internationally standardised quality controls that the analyser automatically checked to
confirm validity of our results. One disadvantage was that the assay could only run on
one  specialised  analyser,  which  was  rarely  used.  This  meant  that  I  had  to  learn  to
maintain and organise the servicing of the equipment. A key weakness of the Millipore
multi-analyte assay was its inability to detect the low concentrations of active GLP-1
and glucagon in our samples. This led us to use Millipore's high sensitivity GLP-1 assay
and  Mercodia's  glucagon  assay.  Their  strengths  were  their  lower  detection  ranges
compared to Millipore's multi-analyte assay. Both Millipore's high sensitivity GLP-1
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assay and Mercodia's glucagon assay also came with multiple international standardised
quality control samples which ensured validity of our results. The Mercodia's glucagon
assay also had the advantage of being read on a standard colour intensity plate reader
which was readily available and regularly maintained. Both assays were easy to set up,
but unfortunately were relatively more expensive. Millipore's high sensitivity GLP-1
assay was read on a  luminometer  plate  reader,  of which there was only one in  our
department. This meant that it was frequently in use, so a degree of coordination was
required to ensure timing assay preparation and access to the analyser. In the future, as
multi-analyte assays become more popular, I hope that the advantages of all three assays
can be combined into one bespoke multi-analyte assay. This could either occur through
combining  analyte  beads  from  other  assays  or  by  developing  bespoke  'in  house'
glucagon and active-GLP-1 analyte beads that can be used on Millipore's multi-analyte
assay.  
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4. EXPLORE GUT HORMONE AXIS IN PATIENTS WITH TYPE 1 DIABETES  
4.1 Exploring progression of Type 1 diabetes and effect on other gut hormones 
The DCCT study in the 1980's firmly established the link between the decline in C-
peptide levels and the duration of type 1 diabetes [185]. Subsequent studies have also
shown that glucagon levels slowly increase over the first year following diagnosis of
type  1  diabetes  [80].  However,  there  is  very  little  research  exploring  the  effect  of
duration of type 1 diabetes on other gut  hormones.  The incretins  were of particular
interest  as the physiological  potential  of incretins  to stimulate insulin  secretion in a
glucose dependent manner had been demonstrated in insulin resistant type 2 diabetes,
but there was limited research into type 1 diabetes. The other group of gut hormones of
interest were those that influence satiety. PP, PYY, Ghrelin and Leptin are markers of
adiposity and satiety. In individuals with type 1 diabetes there is a need to administer
exogenous insulin to utilise and store carbohydrates in adipose tissue. It is unknown
whether the decline in beta cell function has any effect on these networks of hormones
that control adipose tissue and satiety. 
4.2 Method used to explore gut hormones in type 1 diabetes
Samples were collected according to the optimised collection method as described in
chapter 3 from participants from the CDRD study and ExTOD study. Samples were
stored  at  -80°C and  then  analysed  using  the  Millipores  human  metabolic  hormone
magnetic bead panel luminex kit for C-peptide, active ghrelin, GIP, Leptin, PYY and
PP;  Millipore  high  sensitivity  active-GLP-1  assay  and  Mercodia  Glucagon  assay.
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Statistical analysis of the results of samples taken at 0min, 30min, 90 minute, alongside
calculated results for 90 minute Area Under the Curve (AUC 90min) were performed
using GraphPad software (Prism 6, GraphPad Software Inc, USA). Participants were
divided into the following three groups according to their duration of type 1 diabetes:
Group 1) healthy individuals
Group 2) individuals with diabetes for less than 2 years
Group 3) individuals with diabetes for more than 2 years 
4.3 Demographic results of the groups in the analysis
The demographics  of  the  groups  according to  duration  of  diabetes  was  analysed to
explore any potential significant confounding factors (see table 4.1)
Mean +- SD Healthy Controls
(n=23)
DMT1 -
duration<2yrs
(n=28)
DMT1 -
duration>2yrs
(n=21)
Age 43yrs +- 13.5 28yrs+-8.4 *** 50yrs+-15.8 
Duration of DMT1 na 0.5yrs+-0.3 30yrs+-15.3
BMI 24kg/m2+-4.8 25kg/m2+-3.7 27kg/m2+-5.9
% female 61% 32% 48%
Table 4.1: Demographics of the participants by analysis groups. Statistical analysis with 
Kushmal-Wallis and Chi-squared. [*** P<0.001]
Analysis of the groups revealed a significant difference (P<0.001) in the age of those
participants with type 1 diabetes for <2yrs duration compared to the other two groups.
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This difference would introduce a confounding factor that will need to be taken into
consideration when interpreting subsequent results. There was no significant difference
in age between the healthy controls and those with type 1 diabetes for >2yrs.  There was
no statistical difference in female percentages between all groups. Also, there was no
statistical difference in body mass index (BMI) between all groups.
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4.4 Results of gut hormone analysis in individuals with type 1 diabetes
4.4.1 Analysis of C-peptide
All samples collected from participants who undertook a standard volume mixed meal
stimulated test  were processed using  Millipores human metabolic hormone magnetic
bead panel luminex kit to detect levels of C-peptide. Results were then analysed using
Graphpad software.
 
Figure  4.1  :  C-peptide  mean  and  standard  deviations  for  the  three  groups [healthy
controls, subjects with duration of type 1 diabetes <2yrs, subjects with duration of type
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1 diabetes >2yrs] (a) fasting, (b) 30 minutes, (c) 90 minutes, (d) Area Under Curve 0-
90minutes.  Statistical  analysis  with  Kruskal–Wallis  was  utilised  to  find  significant
differences [legend: (ns (p>0.05), * (p<0.05), **(p<0.01), ***(p<0.001)].
The results showed a significant decline in C-peptide with duration of diabetes. Further
statistical analysis was undertaken to determine the confidence intervals and suitability
of C-peptide to differentiate between healthy controls and those with a diagnosis of type
1 diabetes (see Table 4.2). The data from these groups was also analysed with receiver
operated curves (ROC) to determine sensitivity and specificity of both the 30 minute or
90 minute stimulated C-peptide levels for the healthy compared to duration of diabetes
<2yrs (see Figure 4.2).
Healthy DMT1 – duration 
<2yr 
DMT1 – duration 
>2yr
Fasting Mean (SD)
[95% CI] (pg/nl)
1470 (570)
[1230 - 1720]
1000 (490)
[820 - 1190]
27 (60)
[0-56]
30min Mean (SD)
[95% CI] (pg/nl)
4630 (2370)
[3610-5660]
1760 (940)
[1400-2120]
42 (85)
[0-85]
90min Mean (SD)
[95% CI] (pg/nl)
5120 (1970)
[4260-5970]
2700 (1200)
[2250-3160]
68 (150)
[0-140]
Table 4.2: C-peptide mean, standard deviation and 95% confidence intervals for healthy 
volunteers, those with duration of  <2yrs  and duration >2yrs of type 1 diabetes.
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Figure  4.2  :  C-peptide  ROC graph comparing  the  two  groups  [healthy  controls  vs
subjects with type 1 diabetes with duration <2yrs]. (a)30minute C-peptide (pg/ml) ROC
area=0.90 with  a  cut  off  value of  <1600 pg/ml providing a  specificity  of  95% and
sensitivity of 55%. (b) 90minute C-peptide (pg/ml) ROC area=0.87 with a cut off value
of <2960 pg/ml providing a specificity of 95% and sensitivity of 65%.
The  results  from these  analysis  suggest  that  both  a  30  minute  (ROC=0.90)  and  90
minute (ROC=0.87) meal stimulated C-peptide level have good diagnostic accuracy to
differentiate between healthy controls and those with type 1 diabetes.  
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4.4.2 Analysis of GIP
All samples collected from participants who undertook a standard volume mixed meal
stimulated test  were processed using Millipores human metabolic hormone magnetic
bead  panel  luminex  kit  to  detect  levels  of  GIP.  Results  were  then  analysed  using
Graphpad software.
Figure 4.3 : GIP means and standard deviations for the three groups [healthy controls,
subjects with duration of type 1 diabetes <2yrs, subjects with duration of type 1 diabetes
>2yrs]  (a) fasting, (b) 30 minutes, (c) 90 minutes, (d) Area Under Curve 0-90minutes.
Statistical  analysis  with  Kruskal–Wallis  was  utilised  to  find  significant  differences
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[legend: (ns (p>0.05), * (p<0.05), **(p<0.01), ***(p<0.001)].
These results suggest there is no statistical difference in GIP levels between the three
groups at all time points as well as Area Under the Curve 0-90minutes.
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4.4.3 Analysis of GLP-1
All samples collected from participants who undertook a standard volume mixed meal
stimulated test were processed using Millipores high sensitivity active-GLP-1 ELISA to
detect levels of active-GLP-1. Results were then analysed using Graphpad software.
Figure 4.4 : Active GLP-1 means and standard deviations for the three groups [healthy
controls, subjects with duration of type 1 diabetes <2yrs, subjects with duration of type
1 diabetes >2yrs] (a) fasting, (b) 30 minutes, (c) 90 minutes, (d) Area Under Curve 0-
90minutes.  Statistical  analysis  with  Kruskal–Wallis  was  utilised  to  find  significant
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differences [legend: (ns (p>0.05), * (p<0.05), **(p<0.01), ***(p<0.001)].
These results suggest there is no statistical difference in active-GLP-1 levels between all
three groups at all time points as well as Area Under the Curve 0-90minutes.
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4.4.4 Analysis of Leptin
All samples collected from participants who undertook a standard volume mixed meal
stimulated test  were processed using Millipores human metabolic hormone magnetic
bead panel  luminex kit  to  detect  levels  of  leptin.  Results  were then  analysed using
Graphpad software.
Figure 4.5 : Leptin means and standard deviations for the three groups [healthy controls,
subjects with duration of type 1 diabetes <2yrs, subjects with duration of type 1 diabetes
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>2yrs] (a) fasting, (b) 30 minutes, (c) 90 minutes, (d) Area Under Curve 0-90minutes.
Statistical  analysis  with  Kruskal–Wallis  was  utilised  to  find  significant  differences
[legend: (ns (p>0.05), * (p<0.05), **(p<0.01), ***(p<0.001)].
These results suggest there is no statistical difference in leptin levels between all three
groups at all time points as well as Area Under the Curve 0-90minutes.
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4.4.5 Analysis of Pancreatic Polypeptide
All samples collected from participants who undertook a standard volume mixed meal
stimulated test  were processed using Millipores human metabolic hormone magnetic
bead panel luminex kit to detect levels of pancreatic polypeptide (PP). Results were then
analysed using Graphpad software.
Figure 4.6: Pancreatic Polypeptide means and standard deviations for the three groups
[healthy controls, subjects with duration of type 1 diabetes <2yrs, subjects with duration
of type 1 diabetes >2yrs]  (a) fasting, (b) 30 minutes, (c) 90 minutes, (d) Area Under
Curve  0-90minutes.  Statistical  analysis  with  Kruskal–Wallis  was  utilised  to  find
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significant differences [legend: (ns (p>0.05), * (p<0.05), **(p<0.01), ***(p<0.001)].
These results suggest there is no statistical  difference in PP levels between all  three
groups at all time points as well as Area Under the Curve 0-90minutes.
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4.4.6 Analysis of PYY
All samples collected from participants who undertook a standard volume mixed meal
stimulated test  were processed using Millipores human metabolic hormone magnetic
bead  panel  luminex  kit  to  detect  levels  of  PYY.  Results  were  then  analysed  using
Graphpad software.
Figure 4.7: Peptide YY means and standard deviations for the three groups [healthy
controls, subjects with duration of type 1 diabetes <2yrs, subjects with duration of type
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1 diabetes >2yrs]  (a) fasting, (b) 30 minutes, (c) 90 minutes, (d) Area Under Curve 0-
90minutes.  Statistical  analysis  with  Kruskal–Wallis  was  utilised  to  find  significant
differences [legend: (ns (p>0.05), * (p<0.05), **(p<0.01), ***(p<0.001)].
These  results  suggest  there  is  a  statistically  lower  level  of  PYY in  the  group  of
individuals with type 1 diabetes group for >2yrs compared to those with diabetes <2yrs
at time points 0min, 30min and AUC 0-90min and only just being non significant at 90
minutes (p=0.55). Level of PYY at 0min were also statistically lower in the healthy
controls compared to those with duration of type 1 diabetes <2yrs, but no different to
those with type 1 diabetes for >2yrs.
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4.4.7 Analysis of Active Ghrelin
All samples collected from participants who undertook a standard volume mixed meal
stimulated test  were processed using Millipores human metabolic hormone magnetic
bead panel luminex kit to detect levels of active ghrelin. Results were then analysed
using Graphpad software.
Figure 4.8: Active ghrelin mean and standard deviations for the three groups [healthy
controls, subjects with duration of type 1 diabetes <2yrs, subjects with duration of type
1 diabetes >2yrs] (a) fasting, (b) 30 minutes, (c) 90 minutes, (d) Area Under Curve 0-
90minutes.  Statistical  analysis  with  Kruskal–Wallis  was  utilised  to  find  significant
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differences [legend: (ns (p>0.05), * (p<0.05), **(p<0.01), ***(p<0.001)].
The results showed a significant decline in active ghrelin with the duration of diabetes
in a similar fashion to that seen in the C-peptide analysis. Therefore further analysis was
undertaken to determine if active ghrelin could also aid differentiation between healthy
controls and those within two years of diagnosis of type 1 diabetes. Table 4.3 shows the
analysis of the groups and their confidence intervals. The data was then analysed with
receiver operated curves (ROC) to determine sensitivity and specificity of a 0 minute or
90 minute stimulated active ghrelin (see figure 4.9).
Healthy DMT1 – duration 
<2yr 
DMT1 – duration 
>2yr
Fasting Mean (SD)
[95% CI] (pg/ml)
222 (147)
[159 - 286]
122 (68)
[97 - 147]
97 (61)
[69-124]
30min Mean (SD)
[95% CI] (pg/ml)
116 (74)
[84-148]
74 (35)
[60-86]
66 (45)
[45-86]
90min Mean (SD)
[95% CI] (pg/ml)
115 (84)
[79-151]
65 (40)
[50-80]
51 (37)
[34-68]
Table 4.3: Active ghrelin mean, standard deviation and 95% confidence intervals for 
active ghrelin in healthy volunteers, those with duration of type 1 diabetes <2yrs and 
duration >2yrs.
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Figure 4.9: Active ghrelin ROC graphs compares the two groups [healthy controls vs
subjects with type 1 diabetes with duration <2yrs]. (a)0minute active ghrelin (pg/ml)
ROC area=0.72 with a cut off value of <64pg/ml providing a specificity of 95% and
sensitivity of 27%. (b) 90minute active ghrelin (pg/ml) ROC area=0.72 with a cut off
value of <40pg/ml providing a specificity of 95% and sensitivity of 30%.
Results  from  the  ROC  curves  suggest  that  both  a  0  minute  and  90  minute  meal
stimulated active ghrelin levels have only a fair diagnostic accuracy in differentiating
between healthy volunteers and those with duration of type 1 diabetes <2yrs. Therefore
these results were not as accurate as those for C-peptide and would not be recommended
for use in clinical practice.  
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4.4.8 Analysis of Glucagon
All samples collected from participants who undertook a standard volume mixed meal
stimulated test  were processed using Mercodia Glucagon ELISA to detect  levels  of
glucagon. Results were then analysed using Graphpad software.
Figure  4.10:  Glucagon  mean  and  standard  deviations for  the  three  groups  [healthy
controls, subjects with duration of type 1 diabetes <2yrs, subjects with duration of type
1 diabetes >2yrs]  (a) fasting, (b) 30 minutes, (c) 90 minutes, (d) Area Under Curve 0-
90minutes.  Statistical  analysis  with  Kruskal–Wallis  was  utilised  to  find  significant
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differences [legend: (ns (p>0.05), * (p<0.05), **(p<0.01), ***(p<0.001)].
These  results  suggest  that  there  is  a  statistically  higher  level  of  glucagon  in  those
individuals with  type 1 diabetes for <2 years compared to healthy controls at 30min,
90min and AUC 0-90min, but not for 0min. Also, in line with other published data, our
results  show that  paradoxically  glucagon  levels  increase  rapidly  during  the  first  30
minutes of a meal stimulated test in both healthy controls and those individuals with
type 1 diabetes. Only at the 90 minute timepoint do levels start to significantly decline
to that seen in the fasted state. This is counter intuitive as in the fed state there is less
chance of hypoglycaemia then in the fasting state. It was therefore hypothesised that
other gut hormones may be influencing this change in glucagon levels with the most
likely candidates being either a glucose dependent hormone (i.e. insulin) or an incretin. 
4.4.8.1 Method used to explore the initial rise in glucagon.
The method used involved calculating the initial 30 minute change in level (Δ 30min
level) for each gut hormone and comparing it to the  Δ 30min level of glucagon. This
was done using Graphpad software. As insulin was a potential candidate hormone, the
cohort was split into healthy controls, those individuals with positive C-peptide type 1
diabetes, and those individuals with negative C-peptide type 1 diabetes (as defined by
the widely accepted standard of a 90 minute stimulated C-peptide level of  <200pg/ml)
[159].
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4.4.8.2 Results from exploring the paradoxical rise in glucagon
Below are the results of statistical analysis, comparing the change in glucagon levels
over the initial 30 minutes (Δ30 min) of the meal stimulated test to changes in levels of
gut hormones over the same time period for healthy controls, individuals with positive
C-peptide type 1 diabetes and individuals with negative C-peptide type 1 diabetes.
Table 4.4 Pearsons correlation coefficient (r) and significance value (p) for  change in
glucagon  levels  over  initial  30  minutes  (Δ30  min) versus  change  in  levels  of  gut
hormones  over  initial  30  minutes  (Δ30  min) for  healthy  controls,  individuals  with
positive C-peptide type 1 diabetes,  individuals with negative C-peptide type 1 diabetes
and combined cohort of healthy controls and those with type 1 diabetes.   Legend: ns
means p>0.05. 
There were three statistically significant correlations found between the Δ30 min levels
of glucagon and  Δ30 min levels of other gut hormones. All of the correlations were of
moderate  strength and no identical  correlations  occurred in  all  three cohorts.  In  the
healthy controls a moderately strong correlation was found for active ghrelin (r=0.44
p=0.04).  In  the  individuals  with  positive  C-peptide  type  1  diabetes  a  moderate
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Δ30 min Glucose p=0.24 n/a p=0.47 p=0.21
Δ30 min C peptide  p=0.74 p=0.20 n/a p=0.21
Δ30 min GLP-1 p=0.91 p=0.001 r=0.57 p=0.70 p=0.10
Δ30 min Ghrelin p=0.036 r=0.44 p=0.26 p=0.65 p=0.011 r=0.3 
Δ30 min GIP p=0.23 p=0.29 p=0.45 p=0.23
Δ30 min Leptin p=0.71 p=0.12 p=0.52 p=0.21
Δ30 min PP p=0.76 p=0.011 r=0.45 p=0.27 p=0.25
Δ30 min PYY p=0.70 p=0.16 p=0.36 p=0.56
Δ30 min glucagon in 
healthy controls
Δ30 min  glucagon in 
positive c-peptide type 
1 diabetes 
Δ30 min glucagon in 
negative c-peptide type 
1 diabetes 
Δ30 min glucagon in 
combined cohort of 
healthy controls and 
type 1 diabetes 
correlation  was  found for  active-GLP-1 (r=0.57  p=0.001)  as  well  as  for  Pancreatic
Polypeptide (r=0.45 p=0.011).  No correlations were found in the negative C-peptide
cohort with type 1 diabetes. When the cohort of healthy controls, positive and negative
c-peptide diabetes were combined then active ghrelin remained significantly correlated
to Δ30 min levels of glucagon, but only weakly. 
4.4.8.3 Discussion on exploring the initial rise in glucagon
Unfortunately, no single unifying hormone was found to be significantly correlated in
all individual groups to explain the initial 30 minute rise of glucagon. In the combined
cohort there was a weakly significant correlation between active ghrelin and the initial
30 minute rise of glucagon. This suggests that it is unlikely that one of the hormones
explored  in  this  research  is  solely  responsible  for  the  paradoxical  Δ 30min  rise  in
glucagon concentrations. This does not exclude the possibility that multiple hormones
may  be  involved,  or  that  there  is  another  hormone  that  we  haven't  yet  explored.
However, our results did reveal one interesting negative finding which was that there
was no correlation between the  Δ 30min levels of glucagon for either glucose or C-
peptide.  This  suggests  that  the  mechanism  is  probably  neither  glucose  nor  insulin
dependent, but could indicate that either the presence of food in the gut or even taste
might have a role in stimulating the rise in glucagon. This proposed mechanism would
also fit with the observed correlation with active-ghrelin. 
In order to localise the stimuli for glucagon secretion in the gut then an in vivo model
that enables different parts of the gut to be cannulated would be required. Then the
various levels of the gut (e.g. mouth, stomach, first part of the duodenum and ileum)
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could  be  independently  stimulated  with  a  mixed  meal  to  determine  the  level  that
provides the most significant increase in  Δ 30min level of glucagon. The results may
have  significant  implications  for  individuals  with  type  1  diabetes  who  undergo
metabolic  surgery  (e.g.  gastric  band,  gastric  bypass,  duodenal  switch,  etc)  as  the
operation could be potentially tailored to induce the greatest glycaemic benefit.
4.5 Discussion
The cohort of patients studied in this research were all recruited from a single centre,
but  from  two  separate  studies  (a  lifestyle  intervention  study  -  ExTOD  and  an
observational study – CDRD). These studies were exploring different aspects of the
pathogenesis of type 1 diabetes. The Exercise in Type One Diabetes (ExTOD) study was
recruiting individuals with new onset type 1 diabetes and motivating them to take more
exercise to see if it would preserve beta cell function.  The Chronic Disease Research
into Diabetes study was recruiting individuals with all types of diabetes as well as a
separate cohort of healthy controls, to explore the chronic disease burden of diabetes.
The combined cohort of healthy controls and individuals with type 1 diabetes from both
studies underwent a meal stimulated test to explore their gut hormone levels. Thus, the
samples analysed here were from two separate  populations which were not actively
matched  to  ensure  similar  demographics.  We  acknowledge  that  without  adequate
matching we could introduce confounding factors into our data analysis. 
The subjects with type 1 diabetes from the two cohorts were split into two groups in 
order to explore the effect that duration of diabetes has on gut hormone levels: 
Group 1) individuals with diabetes for less than 2 years
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Group 2) individuals with diabetes for more than 2 years
In fact the mean duration of diabetes in the group with a duration of diabetes <2yrs was
0.5 years and in the group with a duration of diabetes >2 years was 30yrs. Thus, the
grouping  could  be  misleading to  the  casual  reader  if  they  were  to  imagine  a  clear
separation between the groups at 2 years. In essence, it is important to interpret the data
as from a group with acute onset type 1 diabetes and a group with chronic duration of
type  1  diabetes.  If  the  opportunity  were  to  arise  whereby  this  research  could  be
undertaken  with  a  larger  population  of  matched  participants,  it  would  be  better  to
compare gut peptide levels according to a more evenly distributed range of diabetes
duration. 
As  exogenous  insulin  is  essential  for  individuals  with  type  1  diabetes,  then  serum
insulin levels do not always correlate  with the endogenous insulin  secretion of beta
cells.  To  determine  endogenous  insulin  secretion,  and  thus  beta  cell  function,  it  is
necessary to measure the levels of the co-secreted peptide - 'C-peptide'. Results from
our analysis of C-peptide show that beta cell function is highest in healthy controls and
lowest in those with chronic type 1 diabetes. These results are in line with those of the
DCCT trial, confirming both fasting and 90minute stimulated C-peptide levels decline
with duration of type 1 diabetes [185]. It is worth noting that currently both fasting and
90  minute  stimulated  C-peptide  levels  are  used  in  clinical  practice.  However,  a  30
minute stimulated C-peptide level is not currently used. Our results demonstrate that a
30 minute stimulated C-peptide is as specific and of similar sensitivity to that of a 90
minute C-peptide level for aiding the diagnosis of type 1 diabetes (30min c-peptide
<1600pg/ml  (95%  sensitivity,  55% specificity);  90min  c-peptide  <2960pg/ml  (95%
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sensitivity,  65% specificity)).  However,  even at  these levels,  5% of cases of type 1
diabetes may be missed with wrongly classified type 1 diabetes occurring in 35% of the
90min c-peptide samples and 45% of the 30min c-peptide samples.  
Further  research  is  needed  to  determine  which  test  has  the  best  sensitivity  and
specificity in differentiating between new onset type 2 diabetes and type 1 diabetes. Not
least  considering  the  low numbers  used  in  this  research  sample.  This  is  especially
important when considering that the phenotypical distinction between type 1 and type 2
diabetes is becoming increasingly blurred. The classical phenotype of new onset type 1
diabetes  is  of  a  thin  individual,  whilst  in  contrast  the  clinical  phenotype  of  type  2
diabetes is  that of an obese individual.  This distinction is  being complicated by the
obesity epidemic. The increasing prevalence of obesity has resulted in ~20% of under
18 year olds now being classed as obese, resulting in an increasing prevalence of young
type 2 diabetes [186]. In ambiguous cases clinicians are frequently turning to anti-islet
antibody levels to help differentiate between an obese individual with new onset type 1
or type 2 diabetes. 
The clinical utility of a same day combined fasting and 30minute stimulated C-peptide
test should not be underestimated. It could provide a time and cost efficient means of
increasing diagnostic accuracy over current clinical diagnostic skills, either alone or in
combination with other biomarkers ie. anti-islet antibody levels. To determine the utility
of a 30 minute C-peptide, a new prospective study would be required. This would need
to be performed with a 'real world' population, specifically targeting ambiguous cases of
early onset type 2 diabetes and type 1 diabetes, as our study population was small and
unrepresentative of the population of cases that clinicians would face. However, data
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from our  and  other  studies  could  be  used  for  power  calculations  to  determine  the
appropriate  study sample  size.  Only after  this  has  been completed could  the  utility,
sensitivity  and specificity  of a 30 minute stimulated C-peptide be determined. If  its
accuracy is confirmed then it could have a key place in the early implementation of
immuno-modulating therapy to delay the progression of early onset type 1 diabetes.
However, it is important to note that whilst it may help distinguish between type 1 and
type 2 diabetes, it may not have a use in detecting other forms of diabetes (e.g. maturity
onset diabetes of the young (MODY), gestational diabetes, latent autoimmune diabetes
of adulthood (LADA), drug induced diabetes, etc).   
The secretion of incretins occurs following the consumption of food. As food enters the
gut, incretins stimulate insulin secretion from beta cells. If incretin homeostasis were to
be adversely affected in type 1 diabetes then there could be a role for exogenous incretin
supplementation. However, our results found that both active-GLP-1 and GIP levels are
not  significantly  different  in  individuals  with  type  1  diabetes  compared  to  healthy
controls. This suggests that physiological incretin hormone secretion is independent of
beta  cell  function  and  unaffected  by  their  decline.  Although  physiological  incretin
supplementation  is  unlikely  to  benefit  individuals  with  type  1  diabetes,  it  does  not
exclude  the  possibility  that  supra-physiological  levels  may  benefit  insulin  resistant
individuals with type 1 diabetes. 
As the consumption of food causes a rise and subsequent decline in incretin levels, then
this could potentially be used as a measure of gut transit time. Our results suggest that
this normally occurs within a 90 minute time frame. Current means of measuring gut
transit time include swallowing radio-opaque contrast medium before performing timed
93
intervals of x-rays to observe the transit of the contrast through the gut, thus exposing
an  individual  to  multiple  doses  of  radiation.  If  a  future  study  could  demonstrate  a
method of accurately measuring gut transit time through incretin levels, then this could
provide a method that does not expose individuals to radiation. This would facilitate
investigations of conditions such as gastroparesis or gastric dumping syndrome. 
Leptin acts as an appetite stimulant and is released from adipose tissue. Levels of leptin
slowly decline following the ingestion of food. However, high levels of leptin are seen
in insulin resistance but its importance in type 1 diabetes is unknown.  Leptin analogue
drugs are in development and are aimed at improving insulin sensitivity and aiding in
weight loss. The results of our analysis confirm that leptin still declines in individuals
with  type  1 diabetes  following ingestion of  the  meal.  Also,  there  was no statistical
difference in Leptin levels between the three groups suggesting that duration of type 1
diabetes does not affect secretion of leptin. As the homeostasis of leptin does not appear
to be affected by the pathogenesis of type 1 diabetes, then leptin analogues may have a
niche role in insulin resistant individuals with type 1 diabetes. As the prevalence of
obese  individuals  with  type  1  diabetes  increases,  leptin  may  become  an  important
marker for insulin resistance in individuals with type 1 diabetes.  
Histopathological analysis of pancreatic tissue from individuals with new onset type 1
diabetes has revealed an infiltrative cellular and inflammatory process that leads to beta
cell  death  [187].  As  beta  cells  share  a  common  developmental  cell  linage  with
neighbouring  endocrine  cells,  then  this  process  could  affect  other  islet  cells.  As
pancreatic polypeptide secreting cells are co-localised within the islet then they may
also  be  at  risk of  being  damaged.  If  this  were  to  occur  we would  expect  to  see a
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progressive decline in PP secretion with duration of type 1 diabetes. Our results show no
statistical difference in circulating levels of PP between the groups. This suggests that
either PP cells are protected from the inflammatory process or that PP secretion occurs
outside of the Islets of Langerhans. It is most likely that PP cells are protected, but to
help determine this then either PP levels would need to be measured in humans (or
animals) that had undergone a total pancreatic resection or alternatively the number of
PP secreting cells would need to be measured in islets from samples taken from humans
(or animal models) with varying durations of type 1 diabetes.  
PYY is released from enteroendocrine cells in the gut in response to ingestion of food.
As yet no role has been found for its control of glucose homeostasis in type 1 diabetes.
The results from this study are challenging to interpret, as statistical differences between
the groups were detected. Firstly, fasting levels were higher in those with a diabetes
duration of <2yrs compared to healthy controls or those with longer duration of type 1
diabetes.  This  difference  disappears  on  ingestion  of  the  mixed  meal.  However,  the
statistically  lower  levels  of  PYY in  the  participants  with  >2yrs  duration  of  type  1
diabetes compared to <2yrs duration persists. These results are not in line with what was
anticipated. One possible explanation is that those with a duration of type 1 diabetes of
<2yrs were statistically younger than those from the other cohorts, potentially making
PYY a marker for ageing or activity. This has been loosely proposed in other studies,
but would require further research before we can confidently say that this conclusion
can be drawn [128]. 
Ghrelin is also secreted by enteroendocrine cells in the stomach, but unlike other gut
hormones the stretching of the stomach by food inhibits its secretion. There is no known
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mechanism that links beta cell function to ghrelin levels. However, our results revealed
significantly lower levels of active ghrelin in individuals with type 1 diabetes compared
to healthy controls at  both fasting and 90 minutes.  It  is  tempting to propose a new
mechanism that links active ghrelin secretion to the pathogenesis of type 1 diabetes but
for the fact that active ghrelin levels are influenced by food types  [188]. High protein
diets tend to lead to lower ghrelin levels than standard diets. At diagnosis of new onset
type 1 diabetes, our patients are warned against eating excess carbohydrates to optimise
their glycaemic control. Thus individuals with type 1 diabetes may tend to choose meals
lower in carbohydrates and higher in protein and fibre. If dietary changes had occurred
in this cohort,  then this could potentially explain differences in active ghrelin levels.
However, one key reason for using a standard meal for all participants in this study was
to eliminate the differences in nutrient proportions in the meal used to stimulate the gut
hormones. Unfortunately, as we did not control all meals prior to the test, then these
could  possibly  have  introduced  a  confounding  factor  that  influenced  active  ghrelin
levels. In order to determine the degree that diet influences ghrelin levels, then a similar
study would  be  needed  whereby individuals  with  both  type  1  diabetes  and healthy
controls are matched for dietary habits prior to the test. If dietary influences could be
excluded, then an explanation for our results could be that the pathogenesis of type 1
diabetes directly influences levels of active ghrelin.
Glucagon  is  secreted  by  alpha  cells  in  the  islets  of  Langerhans.  In  the  traditional
'bihormonal' model it is secreted in response to hypoglycaemia, but subsequent research
has suggested it is also secreted in response to food consumption [135], [189].  As alpha
cells share a common embryological origin to beta cells, then the inflammatory process
may also affect them and their ability to secrete glucagon. The analysis of glucagon
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found that fasting glucagon levels were no different in all three groups, but stimulated
levels  (30minutes  and  90  minutes)  were  significantly  higher  in  those  with  diabetes
duration <2yrs compared to either the healthy controls or duration >2yrs. This is in line
with some published data and could be explained by a potential compensatory alpha cell
hyperplasia occurring shortly after the onset of type 1 diabetes [80], [190]. In order to
investigate  this  hypothesis,  further  pancreatic  samples  from individuals  with  type  1
diabetes would need to be histopathologically examined. Alternatively, a non invasive
means to measure alpha cell mass would need to be developed. An international project
run by the Juvenile Diabetes Research Foundation has set up a database of pancreatic
slides from organ donors with type 1 diabetes that we requested permission to access in
order to explore this hypothesis further (see Chapter 6).  
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5.  EXPLORE THE EFFECTS OF MARKERS OF HEALTHY LIFESTYLE ON  
GUT HORMONES IN TYPE 1 DIABETES.  
5.1 Introduction
The pathogenesis of type 2 diabetes is strongly influenced by lifestyle factors such as
obesity, exercise and age that can affect the homeostasis of gut hormones [191]–[193].
The role of lifestyle modifying factors has not been extensively explored in individuals
with type 1 diabetes. One of the aims of the CDRD study was to explore anthropometric
and lifestyle data as potential  disease markers. This data could then be used to compare
gut  hormone levels  to  lifestyle  factors  and  thus  increase  our  understanding of  how
lifestyle  modifying  factors  can  affect  the  homeostasis  of  gut  hormones  in  type  1
diabetes. 
Lifestyle  data  was  collected  from CDRD study  participants  by  means  of  validated
closed answer questionnaires. This method of data collection was utilised due to the low
cost and its high reproducibility. Variable aspects of lifestyle behaviour were considered
for study including eating behaviour, alcohol consumption, physical activity, physical
functional  ability,  cognition,  psychological  wellness  and  fatigue.  As  the  final
questionnaire needed to be an acceptable length for our participants to complete, it was
decided to focus on three key lifestyle behaviours: eating behaviour, physical activity
and psychological wellness. 
When  considering  which  validated  eating  behaviour  questionnaire  to  use  it  became
obvious that both food diaries and food frequency questionnaires were not appropriate
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due  to  their  length.  Food  diary  and  food  frequency  questionnaires  also  provide  a
descriptive result that is better suited for large epidemiology studies rather than a small
observational study. The “Eating Attitudes Test - 26” was also considered due to its
brevity with 26 closed answer questions. The test was free to use as long as permission
was granted. The Eating Attitudes Test is a validated self administered questionnaire
that provides a score that is well correlated to an individuals concern about their diet,
body  weight  or  problematic  eating  behaviour.  Finally,  the  Three  Factors  Eating
Questionnaire  R18 (TFEQ-18) was considered due to  it  containing 6 closed answer
questions  for  three  separate  eating  behaviour  domains  (ie  cognitive  restraint,
uncontrolled  eating  and  emotional  eating)  [184].   The  “cognitive  restraint”  domain
considers any conscious restriction of the consumption of food instead of acting on
internal cues such as hunger and satiety. The “uncontrolled eating” domain measures the
inability  to  control  those  internal  cues  (ie  satiety)  that  lead  to  overeating.  The
“emotional eating” domain measures the likelihood of choosing to eat in response to
negative emotions.  The TFEQ-18 could provide an ordinal measure of the interplay
between internal physiological cues, cognitive and emotional behaviour.  As many gut
peptides  influence  the  internal  cues  of  satiety  and  hunger  I  decided  to  select  the
validated TFEQ-18 as the questionnaire to explore eating behaviour.
A participant's  psychological  wellness  focuses  on  the  experiences  of  anxiety  and
depression  of  which  depression  is  considered  the  more  clinically  important.  Three
commonly used questionnaires were considered; the Hospital Anxiety and Depression
Scale, Becks Depression Inventory and Patient Health Questionnaire-9. The Hospital
Anxiety and Depression Scale is a 14 item self reported questionnaire that provides an
ordinal  value  for  the  level  of  anxiety,  depression  and  overall  emotional  distress  a
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participant is experiencing. However, it does not strongly correlate to clinical diagnosis
of  anxiety  or  depression.  “Beck's  Depression  Inventory”  is  a  13  item self  reported
questionnaire that provides an ordinal value for the level of depression. It is strongly
correlated to diagnostic criteria for clinical depression, but was not selected due to the
payable  fee  for  using it.  Finally  the  Patient  Health  Questionnaire  -  9  (PHQ-9)  was
considered as it is a 9 item self reported questionnaire that is free to use and provides a
value  that  strongly  correlates  to  the  severity  of  clinical  depression  [183],  [194].
Therefore  the  PHQ-9  was  selected  for  its  ability  to  detect  the  clinical  impact  on
psychological wellness. 
Physical  activity  can  be  measured  through  means  of  questionnaires  and  wearable
devices (eg. pedometers, heart rate monitors and GPS tracking accelerometers). Due to
cost of these devices,  a questionnaire approach was chosen. The ideal questionnaire
would  cover  both  physical  activity  and  inactivity.  Activity  diaries  and  logs  were
considered, but it was felt that prospectively they would be unacceptably time intensive
for our participants and if used retrospectively then they could be open to significant
recall error. The “International Physical Activity Questionnaires - short” and “Global
Physical Activity Questionnaire” are both validated and relatively short questionnaires
that covered aspects of both physical activity and inactivity. Both are validated means of
calculating physical activity as metabolic equivalents (amount of energy per kg of body
mass  expended  per  hour)  and  physical  inactivity  (total  amount  of  awake  sedentary
time). The International Physical Activity Questionnaire – short version consists of 7
closed questions and the Global Physical Activity Questionnaire consists of 16 closed
questions.  The  International  Physical  Activity  Questionnaire  –  short  version  was
selected for its brevity and ability to measure both physical activity and inactivity.
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It had been decided that an acceptable length for an educated participant to complete the
combined questionnaires would be under 15 minutes. A volunteer from our laboratory
was timed at completing all three questionnaires (ie Three Factors Eating Questionnaire
R18, Patient Health Questionnaire - 9 and International Physical Activity Questionnaire
– short version). This took them ~19 minutes to complete and they reported difficultly
in accurately answering the physical activity part of the International Physical Activity
Questionnaire. Therefore, the physical activity part of the International Physical Activity
Questionnaire was removed and the physical inactivity part was kept. This enabled the
questionnaire to be completed in under 15 minutes.
5.2  Methods  used  to  explore  the  influence  of  lifestyle  factor's  on  gut  hormone
levels.
The measurements  of  body mass  index (BMI),  sedentary  time,  depression,  age  and
eating behaviour were accessed from the CDRD database for those participants that had
undergone  a  meal  stimulated  test.  In  order  to  exclude  the  influence  of  residual
endogenous insulin secretion, the cohort of patients was split into two groups:
1. Healthy controls 
2. Individuals with negative c-peptide levels type 1 diabetes (less than 200pg/ml)
as determined by the 90 minute stimulated time point for c-peptide. 
The results from the lifestyle questionnaires from each group were compared to ensure
there  was  no statistical  difference.  Then the  results  obtained for  gut  hormone level
analysis  for  90  minute  stimulated  area  under  the  curve  (AUC 0-90  minutes)  were
compared  to  lifestyle  factors  (age,  sedentary  time,  BMI,  depression  and  eating
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behaviour) using Graphpad software.  
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5.3 Results of the analysis of lifestyle factors influence on gut hormone levels
Comparisons of the lifestyle questionnaire responses between the healthy controls and 
those with negative c-peptide type 1 diabetes demonstrated no statistical difference (see 
Table 5.1). 
Healthy Negative c-peptide
DMT1
Statistical difference
n 23 17 p>0.05
Mean age [SD] 42.5 [13.6] 50.7 [15.7] p>0.05
Mean sedentary time
(min) [SD]
173 [113] 203 [153] p>0.05
Mean BMI (kg/m2) 
[SD]
24.3 [4.9] 27.5 [6.7] p>0.05
Mean PHQ-9 score 
[SD]
2.2 [2.3] 5.8 [4.5] p>0.05
Mean TFEQ – 
cognitive score [SD]
12.1[2.6] 14.1 [3.7] p>0.05
Mean TFEQ – 
uncontrolled score 
[SD]
17.7 [5.3] 15.2 [4.5] p>0.05
Mean TFEQ – 
emotional score 
[SD]
5.3 [2.0] 5.4 [2.1] p>0.05
Table 5.1: Mean and standard deviations for the group of healthy participants and 
negative c-peptide type 1 diabetes participants. Statistical analysis with Kruskal-Wallis 
was utilised to find significant differences.
  
In order to determine which lifestyle factors influence gut hormone levels in non-
diabetic conditions, the lifestyle questionnaire results from the healthy participants were
compared to their 90 minute area under the curve gut peptide results (see Figures 5.1-
5.8). Then the lifestyle questionnaire results from the negative c-peptide type 1 diabetes 
participants were compared to their 90 minute area under the curve gut peptide results 
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(see Figures 5.9-5.16).   
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Figure  5.1:  Correlation  and  regression
relationships  of  healthy  individuals  90
minute  area  under  the  curve  glucagon
levels  compared  to  age,  average  daily
sedentary  time,  BMI,  PHQ-9  depression
score,  TFEQ-cognitive  score,  TFEQ-uncontrolled  score  and  TFEQ-emotional  score.
Statistical analysis with significance values (p) and Pearsons correlation coefficient (r)
for all statistically significant parameters.
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Figure  5.2:  Correlation  and  regression
relationships  of  healthy  individuals  90
minute area under the curve active GLP-1
levels  compared  to  age,  average  daily
sedentary  time,  BMI,  PHQ-9  depression
score,  TFEQ-cognitive  score,  TFEQ-uncontrolled  score  and  TFEQ-emotional  score.
Statistical analysis with significance values (p) and Pearsons correlation coefficient (r)
for all statistically significant parameters.
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Figure  5.3:  Correlation  and  regression
relationships  of  healthy  individuals  90
minute  area  under  the  curve  C-peptide
levels  compared  to  age,  average  daily
sedentary  time,  BMI,  PHQ-9  depression
score,  TFEQ-cognitive  score,  TFEQ-uncontrolled  score  and  TFEQ-emotional  score.
Statistical analysis with significance values (p) and Pearsons correlation coefficient (r)
for all statistically significant parameters.
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Figure  5.4:  Correlation  and  regression
relationships  of  healthy  individuals  90
minute area under the curve active ghrelin
levels  compared  to  age,  average  daily
sedentary  time,  BMI,  PHQ-9  depression
score,  TFEQ-cognitive  score,  TFEQ-uncontrolled  score  and  TFEQ-emotional  score.
Statistical analysis with significance values (p) and Pearsons correlation coefficient (r)
for all statistically significant parameters.
108
0 10000 20000 30000
0
20
40
60
80
AUC-90min Active ghrelin pg/ml
A
ge
 (y
ea
rs
)
p=ns
0 10000 20000 30000
0
200
400
600
AUC-90min Active ghrelin pg/ml
A
ve
ra
ge
 s
ed
en
ta
ry
 ti
m
e
pe
r d
ay
 (m
in
)
p=ns
0 10000 20000 30000
0
10
20
30
40
50
AUC-90min Active ghrelin pg/ml
BM
I (
kg
/m
2)
p=ns
0 10000 20000 30000
0
5
10
15
20
AUC-90min Active ghrelin pg/ml
PH
Q
-9
p=ns
0 10000 20000 30000
0
10
20
30
AUC-90min Active ghrelin pg/ml
TF
EQ
 C
og
ni
tiv
e
p=ns
0 10000 20000 30000
0
10
20
30
AUC-90min Active ghrelin pg/ml
TF
EQ
 U
nc
on
tr
ol
le
d
p=ns
0 10000 20000 30000
0
10
20
30
AUC-90min Active ghrelin pg/ml
TF
EQ
 E
m
ot
io
na
l
p=ns
Figure  5.5:  Correlation  and  regression
relationships  of  healthy  individuals  90
minute  area  under  the  curve  GIP  levels
compared to  age,  average  daily  sedentary
time,  BMI,  PHQ-9  depression  score,
TFEQ-cognitive score, TFEQ-uncontrolled score and TFEQ-emotional score. Statistical
analysis  with  significance  values  (p)  and  Pearsons  correlation  coefficient  (r)  for  all
statistically significant parameters.
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Figure  5.6:  Correlation  and  regression
relationships  of  healthy  individuals  90
minute area under the curve leptin levels
compared to age, average daily sedentary
time,  BMI,  PHQ-9  depression  score,
TFEQ-cognitive score, TFEQ-uncontrolled score and TFEQ-emotional score. Statistical
analysis  with  significance  values  (p)  and  Pearsons  correlation  coefficient  (r)  for  all
statistically significant parameters.
110
0 10000 20000 30000 40000 50000
0
20
40
60
80
AUC-90min Leptin pg/ml
Ag
e 
(y
ea
rs
)
p=ns
0 10000 20000 30000 40000 50000
0
200
400
600
AUC-90min Leptin pg/ml
A
ve
ra
ge
 s
ed
en
ta
ry
 ti
m
e
pe
r d
ay
 (m
in
)
p<0.01
r=0.59
0 10000 20000 30000 40000 50000
0
10
20
30
40
50
AUC-90min Leptin pg/ml
BM
I (
kg
/m
2)
p<0.001
r=0.84
0 10000 20000 30000 40000 50000
0
5
10
15
20
AUC-90min Leptin pg/ml
PH
Q
-9
p=ns
0 10000 20000 30000 40000 50000
0
10
20
30
AUC-90min Leptin pg/ml
TF
EQ
 C
og
ni
tiv
e
p=ns
0 10000 20000 30000 40000 50000
0
10
20
30
AUC-90min Leptin pg/ml
TF
EQ
 U
nc
on
tr
ol
le
d
p=ns
0 10000 20000 30000 40000 50000
0
10
20
30
AUC-90min Leptin pg/ml
TF
EQ
 E
m
ot
io
na
l
p<0.01
r=0.59
Figure  5.7:  Correlation  and  regression
relationships  of  healthy  individuals  90
minute  area  under  the  curve  PP  levels
compared to age,  average daily sedentary
time,  BMI,  PHQ-9  depression  score,
TFEQ-cognitive score, TFEQ-uncontrolled score and TFEQ-emotional score. Statistical
analysis  with  significance  values  (p)  and  Pearsons  correlation  coefficient  (r)  for  all
statistically significant parameters.
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Figure  5.8:  Correlation  and  regression
relationships  of  healthy  individuals  90
minute  area  under  the  curve  PYY levels
compared to age,  average daily sedentary
time,  BMI,  PHQ-9  depression  score,
TFEQ-cognitive score, TFEQ-uncontrolled score and TFEQ-emotional score. Statistical
analysis  with  significance  values  (p)  and  Pearsons  correlation  coefficient  (r)  for  all
statistically significant parameters.
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Figure  5.9:  Correlation  and  regression
relationships  of  negative  c-peptide  type  1
diabetes participants 90 minute area under
the curve glucagon levels compared to age,
average daily sedentary time, BMI, PHQ-9
depression  score,  TFEQ-cognitive  score,  TFEQ-uncontrolled  score  and  TFEQ-
emotional  score. Statistical  analysis  with  significance  values  (p)  and  Pearsons
correlation coefficient (r) for all statistically significant parameters.
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Figure  5.10:  Correlation  and  regression
relationships of negative c-peptide type 1
diabetes participants 90 minute area under
the curve active glp-1 levels compared to
age,  average  daily  sedentary  time,  BMI,
PHQ-9 depression score, TFEQ-cognitive score, TFEQ-uncontrolled score and TFEQ-
emotional  score.  Statistical  analysis  with  significance  values  (p)  and  Pearsons
correlation coefficient (r) for all statistically significant parameters.
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Figure  5.11:  Correlation  and  regression
relationships of negative c-peptide type 1
diabetes participants 90 minute area under
the curve active ghrelin levels compared to
age,  average  daily  sedentary  time,  BMI,
PHQ-9 depression score, TFEQ-cognitive score, TFEQ-uncontrolled score and TFEQ-
emotional  score.  Statistical  analysis  with  significance  values  (p)  and  Pearsons
correlation coefficient (r) for all statistically significant parameters.
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Figure  5.12:  Correlation  and  regression
relationships of negative c-peptide type 1
diabetes participants 90 minute area under
the  curve  GIP  levels  compared  to  age,
average daily sedentary time, BMI, PHQ-9
depression  score,  TFEQ-cognitive  score,  TFEQ-uncontrolled  score  and  TFEQ-
emotional  score. Statistical  analysis  with  significance  values  (p)  and  Pearsons
correlation coefficient (r) for all statistically significant parameters.
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Figure  5.13:  Correlation  and  regression
relationships of negative c-peptide type 1
diabetes participants 90 minute area under
the  curve  leptin  levels  compared  to  age,
average daily sedentary time, BMI, PHQ-9
depression  score,  TFEQ-cognitive  score,  TFEQ-uncontrolled  score  and  TFEQ-
emotional  score. Statistical  analysis  with  significance  values  (p)  and  Pearsons
correlation coefficient (r) for all statistically significant parameters.
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Figure  5.14:  Correlation  and  regression
relationships of negative c-peptide type 1
diabetes participants 90 minute area under
the  curve  PP  levels  compared  to  age,
average daily sedentary time, BMI, PHQ-9
depression  score,  TFEQ-cognitive  score,  TFEQ-uncontrolled  score  and  TFEQ-
emotional  score. Statistical  analysis  with  significance  values  (p)  and  Pearsons
correlation coefficient (r) for all statistically significant parameters.
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Figure  5.15:  Correlation  and  regression
relationships of negative c-peptide type 1
diabetes participants 90 minute area under
the  curve  PYY levels  compared  to  age,
average daily sedentary time, BMI, PHQ-9
depression  score,  TFEQ-cognitive  score,  TFEQ-uncontrolled  score  and  TFEQ-
emotional  score. Statistical  analysis  with  significance  values  (p)  and  Pearsons
correlation coefficient (r) for all statistically significant parameters.
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The results from the correlations between lifestyle questionnaire responses from the 
healthy participants and their 90 minute area under the curve gut peptide results are 
summarised in table 5.2.   
 
Table 5.2: Summary of significance values (p) and Pearsons correlation coefficient (r) 
for gut peptides (Area Under Curve 0-90minutes) vs lifestyle questionnaires in healthy 
controls. 
In the healthy controls there were many significant correlations between lifestyle factors
and gut hormones. The only strong correlation was between leptin and BMI (r=0.84,
p<0.001).  This  has  previously  been described in  papers  and was anticipated,  as  the
volume of adipose tissue directly influences the levels of leptin secretion  [67]. Other
moderately strong correlations found were between leptin and sedentary time (r=0.59,
p<0.01).  This  again would be expected as sedentary time is  closely associated with
obesity  [195]. Leptin also had a moderately strong correlation with emotional eating
(r=0.59, p<0.01), which has not been reported before, but again would be expected as
comfort eating is associated with obesity  [196]. There was also a moderately strong
correlation between uncontrolled eating and PYY (r=0.59 , p<0.01) and GIP (r=0.59 ,
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Glucagon GLP-1 C-peptide Ghrelin GIP Leptin PP PYY
Sedentary Time p=0.24 p=0.17 p=0.46 p=0.57 p=0.74 p=0.34 p=0.27
Age p=0.66 p=0.38 p=0.43 p=0.92 p=0.48 p=0.22 p=0.85 p=0.66
BMI p=0.25 p=0.37 p=0.09 p=0.68 p=0.15 p=0.48
PHQ9 p=0.68 p=0.42 p=0.1 p=0.72 p=0.89 p=0.75
TFEQ – cognitive p=0.58 p=0.45 p=0.28 p=0.63 p=0.70 p=0.41 p=0.75 p=0.21
TFEQ – uncontrolled p=0.62 p=0.86 p=0.13 p=0.22 p=0.11 p=0.35
TFEQ – emotional p=0.30 p=0.07 p=0.81 p=0.30 p=0.23 p=0.87 p=0.51
p=0.003 
r=0.59
p<0.001 
r=0.84 
p=0.031 
r=0.45 
p=0.02 
r=0.52
p=0.048 
r=0.45
p=0.003 
r=0.59
p=0.004 
r=0.59
p=0.007 
r=0.59
p<0.01). As PYY is a potent appetite suppressing hormone this could suggest that the
behaviour  of  uncontrolled  eating  may  be  partially  due  to  either  ineffective  PYY
signalling or psychological over riding of PYY appetite suppressing mechanisms. 
The results from the correlations between lifestyle questionnaire responses from the 
participants with negative c-peptide type 1 diabetes and their 90 minute area under the 
curve gut peptide results are summarised in table 5.3.
Table 5.3: Summary of significance values (p) and Pearsons correlation coefficient (r) 
for gut peptides (Area Under Curve 0-90minutes) vs lifestyle questionnaires in subjects 
with negative C-peptide type 1 diabetes. 
Our expectation was that results would probably be very similar if type 1 diabetes did
not  influence gut hormone levels.  In the population of individuals with negative C-
peptide levels type 1 diabetes, there was a moderately strong correlation between leptin
and BMI (r=0.68, p<0.01). This was similar to that seen in healthy controls.  However,
unlike the healthy controls there was no correlation between leptin and emotional eating
factors or sedentary time. This was surprising as we would have expected similar results
for both hormones in the healthy controls and individuals with negative C-peptide type
121
Glucagon GLP-1 Ghrelin GIP Leptin PP PYY
Sedentary Time p=0.98 p=0.56 p=0.74 p=0.73 p=0.22 p=0.77
Age p=0.25 p=0.67 p=0.78 p=0.58 p=0.15 p=0.61
BMI p=0.88 p=0.36 p=0.80 p=0.22 p=0.82 p=0.85
PHQ9 p=0.91 p=0.81 p=0.23 p=0.52 p=0.47 p=0.94 p=0.80
TFEQ – cognitive p=0.32 p=0.98 p=0.30 p=0.92 p=0.86 p=0.47 p=0.38
TFEQ – uncontrolled p=0.61 p=0.94 p=0.89 p=0.39 p=0.27 p=0.78 p=0.99
TFEQ – emotional p=0.67 p=0.62 p=0.16 p=0.18 p=0.40 p=0.30 p=0.73
p=0.002 
r=0.71
p=0.005 
r=0.67
p=0.004 
r=0.68
1 diabetes. A possible explanation could be that the population size was too small to
detect this correlation. An alternative explanation could be that eating behaviour and
sedentary time do not correlate to leptin levels in individuals with negative C-peptide
type 1 diabetes, due to either confounding factors such as exercise and dietary advice or
even the disease process.        
There  were  other  new significant  correlations  in  the  population  of  individuals  with
negative c-peptide type 1 diabetes. There was a strong correlation between GIP and
sedentary time (r=0.71, p<0.01). This correlation was unexpected, but there have been
reports  that  GIP levels  are  influenced by physical  activity  [197].   Alternatively this
correlation with GIP could represent an as of yet unexplored adaptive response to the
pathogenesis  of  type  1  diabetes.  To better  understand  this  correlation  between  GIP
levels and sedentary time, a future study may consider comparing markers of physical
activity (e.g. actigraphs, pedometer, international physical activity questionnaires) and
physical fitness (e.g. Metabolic Equivalents of Task, VO2Max, multi-stage fitness test)
with GIP levels in individuals with type 1 diabetes.  
The other moderately significant correlation was between GIP and age (r=0.67, p<0.01).
This again, was unexpected and has not been previously reported in type 1 diabetes.
This may indicate that GIP could be a potential marker of ageing or alternatively, this
could be due to  age being an uncontrolled confounding factor  that  occurred due to
inadequate matching of the cohorts. To explore this further  age matched individuals
with  negative  C-peptide  type  1  diabetes  could  undergo  measurements  of  known
biomarkers of ageing (e.g. advanced glycocylated end products, Insulin Growth Factor-
1, hand grip strength) and common age related confounding factors (e.g. dietary intake,
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exercise, bone health and adrenal function) to see if statistically robust correlation with
GIP levels exist.
  
5.4 Discussion
The method used to explore the influence of type 1 diabetes on the correlations between
lifestyle factors and gut peptides involved multiple statistical comparisons. The use of
multiple  statistical  comparisons  increases  the  likelihood  of  a  statistically  significant
difference  occurring  by  chance  and  thus,  potentially  increase  the  number  of  false
positive results. In the analysis of these results I have focused only on results with a
probability  value  of  <0.01.  This  is  because  there  are  potentially  105  independent
statistical comparisons which could potentially produce 6 false positive results with a p
value of 0.05, but only 1 with a p value of 0.01. However, larger studies of adequately
matched participants would be needed to ensure these results have not arisen by chance
or confounding. 
The gut  hormone level  results  of samples collected from participants  of the CDRD
study were compared to the lifestyle questionnaire responses and anthropometric data
that  was gathered  during  their  meal  stimulated test.  It  was  anticipated  that  lifestyle
factors  such  as  sedentary  time,  BMI,  age,  depression  and  eating  behaviour  may
influence gut hormones in type 1 diabetes. In particular we expected to see at least a
moderate effect with the hormones related to adiposity and satiety. Results from this
study confirmed that the adipose derived leptin  hormone is  strongly correlated with
body mass index in individuals with type 1 diabetes and healthy controls. However, new
and unexpected moderately strong correlations were found in the group of individuals
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with negative C-peptide type 1 diabetes, such as between sedentary time, age and GIP.
These new correlations would require further research to confirm statistical significance
before determining the mechanisms of action. 
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6. EXPLORE THE HISTOPATHOLOGICAL EFFECT OF TYPE 1 DIABETES ON  
GLUCAGON SECRETING CELLS IN THE PANCREAS.  
6.1 Introduction
The  chronic  autoimmune  process  of  type  1  diabetes  is  traditionally  described  as  a
process of cellular infiltration and inflammation in the islets which leads to beta cell
death. The endocrine cells of the islets are derived from a common pluripotent cell line
that,  during  embryological  development,  undergoes  differentiation  into  alpha,  beta,
delta, epsilon and PP cells  [198]. Stem cell research has enabled us to understand this
process of differentiation and has facilitated researchers to reprogram alpha cells into
beta cells [199]. We therefore wished to explore the effect of duration of type 1 diabetes
on the expression of glucagon stained cells in the islets.       
6.2 Method for image analysis of glucagon secreting cells in the pancreas
The Juvenile Diabetes Research Foundation network for Pancreatic Organ donors with
Diabetes  (JDRF nPOD) is  an  online  searchable  database  of  immunohistochemically
stained slide samples taken from donors with diabetes. The database was accessed and
searched for slides taken from donors with type 1 diabetes that had been stained for
glucagon on 4th January 2014. Each donor slide was visually inspected and islets from
each slide were localised. The dimensions of each islet were measured using the JDRF
nPOD online software that is provided with the database. A JPEG (Joint Photographic
Experts Group) image was then taken of four islets from each slide and then the largest
islet by area was selected for analysis (see figure 6.1). The largest islet jpeg image was
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then  opened  and  analysed  using  the  free  open  source  software  “GNU  Image
Manipulation Program (GIMP)” version 2.8 (www.gimp.org). Image analysis involved
cropping the image to the maximum height and width of the islet. The number of pixels
for each image was recorded, before the software digitally subtracted all pixels outside
of the islet from the image leaving the islet on a blank background. The number of
pixels remaining was recorded in order to calculate the actual islet area. The image was
then polarized to differentiate between the blue and brown of the immunohistochemical
staining. The blue from the image was digitally reduced and then subtracted from the
image. Finally the image was converted to grey scale and the contrast increased to allow
calculation of the non white area of the image (see figure 6.2). This area equates to the
area originally stained brown, indicating glucagon secreting cells, as well as cell nuclei.
(See Appendix 3 for further details.) 
Figure 6.1 Image of a typical islet selected for further analysis from the JDRF nPOD 
web database.
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Figure 6.2 Images of a selected islet that has undergone digital manipulation to highlight
the area stained for glucagon, before being turned to monochrome whereby the black 
pixels can be recorded in order to approximate the area of glucagon secreting cells.
6.3 Results of image analysis of glucagon secreting cells in the pancreas
The JDRF nPOD database at the time of access only contained 16 donor slides that had
been stained for glucagon. All donors had type 1 diabetes and negative C-peptide levels,
suggesting the absence of insulin  secreting beta  cells.  There were no healthy donor
slides  available  in the database that  could be used as  control  samples.  Each donors
demographic  details  were  recorded  (see  table  6.1).  The  results  of  the  image
manipulation were compared to age, body mass index (BMI) and duration of diabetes
using Graphpad Software. There was one significant correlation detected  between age
of the donor and the area of glucagon containing cells (r=0.50, P<0.05). 
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Table  6.1  Demographics  of  pancreatic  donors  with  type  1  diabetes  that  underwent
immunohistochemical staining for glucagon.
 
Table 6.2 Significance value (p) and Pearsons correlation coefficient (r) for islet area 
and area stained for glucagon vs duration of diabetes, age and BMI for JDRF nPOD 
donors with type 1 diabetes.  Legend: ns means p>0.05. 
6.4 Discussion of image analysis of glucagon secreting cells
The JDRF nPOD database is an easy to use and important searchable database of donors
with type 1 diabetes. The database also enables slides to be downloaded as image files
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Case ID Diabetes Duration Age Sex BMI % glucagon
6036 34 49 f 25 41624 56.3 23434
6038 37 37 f 31 19148 30.3 5802
6035 28 32 m 27 42051 10.3 4331
6032 n/a 33 m 29 9558 37 3536
6033 28 40 m 24 12564 37.9 4762
6031 35 39 m 24 9992 30.5 3048
6026 14 22 m 24 17488 51.7 9041
6025 19 23 m 27 10344 17.1 1769
6128 31 34 f 22 4081 51.5 2102
6113 1 13 f 24 25177 22.4 5640
6071 17 28 f 19 31698 37.7 11950
6046 8 19 f 25 20598 3.1 639
6045 8 26 m 23 24652 17.5 4314
6042 59 60 f 23 35307 28.7 10133
6040 20 50 f 32 23361 44.8 10466
6039 12 29 f 23 6477 50.8 3290
Islet Area (µm2) Area of glucagon (µm2)
Diabetes Duration Age BMI
ns ns ns
% glucagon ns ns ns
ns p<0.05 r=0.50 ns
Islet Area (µm2)
Area of glucagon (µm2)
to  undergo  image  manipulation.  Unfortunately,  despite  its  large  repository,  it  only
contained 16 donor samples that were stained for glucagon at the time of access. The
database also did not contain any healthy controls that had slides stained for glucagon,
which  limited the statistical  power of  the  database  to  determine  changes  in  area of
glucagon staining cells. Despite these limitations the database is an important expanding
international  resource  that  provides  researchers  with  access  to  pancreatic  slides  of
donors that would not otherwise be readily available.   
The method used to manipulate the images in this research was developed by Dr David
Hughes (author of this thesis), but is based on techniques used in digital photographic
enhancement.  The software  provided by the  website  did  not  allow advanced image
manipulation and so other software was required. Image manipulation software such as
Microsoft  Paint  (Redmond,  Washington,  USA)  and  ImageJ  (Opensource)  were
explored, but did not have the functional ability to polarize colours to facilitate digital
subtraction. The opensource software 'GNU image manipulation program' (GIMP) was
freely available and included advanced image manipulating functions that are normally
found in more expensive commercial products. The method of image manipulation was
refined before reaching the final method used in this research (Appendix 3). The method
was  not  without   imperfections  as  can  clearly  be  demonstrated  by  its  inability  to
digitally  subtract  nuclei  from  the  image.  This  imperfection  does  introduce  a
confounding factor in the analysis. 
The demographics of the donors in the JDRF nPOD database turned out to be skewed
towards those with longer duration of type 1 diabetes, with only one donor having type
1 diabetes for under 2 years. This uneven distribution in demographics limits our ability
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to explore the effect of diabetes duration on glucagon secreting cells. The analysis of
our results suggests that there is no correlation between the duration of diabetes and the
size of the islets or the area stained for glucagon. This could indicate that the area of
glucagon stained cells remains constant despite the duration of type 1 diabetes, but due
to the limited sample size all conclusions should be made with caution. However, a
moderate correlation between area stained for glucagon and age (r=0.50; p<0.05) was
detected. This correlation may indicate that the ageing process in individuals with type 1
diabetes may be associated with an expansion in numbers (or size) of glucagon stained
cells. However, due to the limited sample size available it would be prudent to repeat
the analysis when a larger cohort becomes available. Hopefully, as the database expands
it might be possible to compare glucagon stained areas in healthy controls to those with
type 1 diabetes.
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7. CONCLUSION  
Research into type 1 diabetes has rapidly progressed over the last 100 years leading to
important discoveries that have reduced mortality and morbidity rates. Nevertheless,
there is still much more work needed in order to bring life expectancy in line with that
of the general population. An obesity epidemic has helped by fuelling the investment
into type 2 diabetes research which has expanded our understanding of the hormonal
networks  involved  in  glucose  homeostasis.  Whilst  these  hormones  have  been
extensively researched in type 2 diabetes,  there remains a lack of comprehension for
their role in type 1 diabetes.  
Insulin has been the only effective treatment for type 1 diabetes for nearly a century. For
a similar length of time glucagon administration has been known to treat hypoglycaemia
by raising blood glucose levels. It is becoming apparent that manipulation of other gut
hormones may have a role in treating type 1 diabetes. For instance, our knowledge of
glucagon  has  expanded  significantly  and  it  is  now  known  that  shortly  after  the
consumption  of  food  there  is  an  initial  increase  in  glucagon  stimulation  of
glycogenolysis  and  the  release  of  glucose.  This  new understanding  and  its  clinical
impact on glycaemia has led to clinical trials of glucagon suppressing agents such as
GLP-1 analogues and DPP-4 inhibitors being used in individuals with type 1 diabetes to
control blood glucose levels. The outcomes of these trials have admittedly been mixed
and larger trials that are ongoing may open the gateway for novel treatment options.  
It is also known that the ingestion of food causes the release of the gut derived incretin
hormones (GLP-1 and GIP).  These incretin hormones are known to potentiate insulin
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release in a glucose dependent manner in healthy individuals. In type 2 diabetes this
mechanism of action can be lost and thus drugs are used in type 2 diabetes to reinstate
the incretin effect to  aid in  glycaemic control.  Recent  large clinical trials  of GLP-1
analogues such as the LEADER study have shown that they may have a role to play in
reducing  the  progression  of  cardiovascular  disease  in  type  2  diabetes  [137].  Their
cardiovascular  protective  and  glycaemic  utility  in  type  1  diabetes  remains  largely
unknown.  GIP is  another  incretin  hormone  that  has  a  significant  impact  in  type  2
diabetes with GIP resistance now understood to be a key part of the pathophysiological
process leading to insulin resistance. GIP's importance may not be limited to type 2
diabetes, but in nearly all types of diabetes. To dates, studies in to the role GIP plays in
the pathophysiology of type 1 diabetes are lacking. 
Ongoing research in type 2 diabetes has revealed the importance gut hormones have in
the hypothalamic control of appetite and satiety [200], [201]. Studies into appetite have
demonstrated that insulin and ghrelin significantly stimulate the sensation of hunger,
whilst PP, leptin and PYY can inhibit it.  The hypothalamic centre for the control of
appetite is also influenced by connections to the limbic system that controls mood, as
well as connections from the hind brain that control behaviour. The interplay between
mood, eating behaviour, physical activity and gut hormones is considered an essential
part of an individuals daily glucose homeostasis. In type 2 diabetes this interplay, along
with the effect exogenous insulin has on appetite, is clinically well acknowledged as
having a significant impact on an individuals weight. However, the same interplay and
effect on weight in type 1 diabetes is relatively unexplored. 
Chronic  inflammation  in  the  Islets  of  Langerhans  is  a  hallmark  feature  of  type  1
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diabetes that ultimately leads to beta cell death. The chronic inflammatory process is
mediated via a variety of monoclonal antibodies that target islet related antigens. The
trigger for this process is related to the interaction between an individuals genetic and
environmental susceptibility. Currently frontiers of research are expanding the role of
immuno-modulating therapy in order to reduce the inflammatory process and preserve
functional beta cells. However, these therapies only slow the loss of insulin secreting
beta cells and do not result in their regeneration. To reverse type 1 diabetes either a
transplant of beta cells  must occur or a means of generating new beta cells. Recent
research suggests that endocrine islet cells are derived from a common pluripotent cell
line  [198], [202]. This could mean that there may be a possibility of reprogramming
alpha cells into functioning beta cells. If this was to be a success, an ample supply of
alpha cells would need to be present in an individual with type 1 diabetes regardless of
its duration. To further our understanding of the effects of type 1 diabetes, this thesis has
explored the role of gut hormones and attempted to quantify alpha cell numbers. To do
this it was important to break our aims down into a series of manageable objectives.
One of the initial key objectives was to develop a means of recruiting participants. It
was decided that this would be best achieved through a network of research studies.
This  was  developed  by  collaborating  with  researchers  from  the  ExTOD  study  and
through  the  establishment  of  the  CDRD study.  The  CDRD study was  funded by a
research grant from Novo nordisk and was initially set up as a biological banking and
questionnaire  study.  This  involved  producing  a  workable  protocol  and  securing
appropriate regulatory approval. Subsequently, a substantial protocol amendment was
made to facilitate the set up of a gut hormone sub-study to enable the collection and
analysis of samples. Finally, the protocol and structure of the study was adapted further
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to enable it to be established as a multi-site study. The process from inception to the
refinement of the CDRD study at multiple sites was managed by Dr David Hughes (the
author of this thesis).  
Once a means of recruiting participants was established, it became important to ensure
there was uniformity in collecting samples from participants from the both the ExTOD
study and CDRD gut  hormone sub-study. Therefore the next  main objective was to
develop  valid  methods  for  collecting  and  measuring  gut  hormones.  It  was  well
recognised that  certain gut  hormones degrade rapidly  if  they  are  not  collected  with
appropriate enzyme inhibitors, but there was a lack of clarity in regards to gut hormone
assays. Initially it was decided to only use participants recruited at the Queen Elizabeth
Hospital  Birmingham site  for  this  subsecton  of  the  study  and  that  they  should  all
undergo the same standardised meal stimulated test. Comparisons were made between
collection methods and a variety of assays were compared. Attempts to optimise the
assays function came to many frustrating dead ends and the process took longer than
was anticipated to complete. However, the final outcome was a reproducible process
that we were confident has accurately and reproducibly measured gut hormone levels.
In  retrospect,  I  now  recognise  that  with  more  time  and  planning  a  more  robust
methodology could have been utilised to determine the optimum means of collecting
samples  and  measuring  gut  hormones.  Our  chosen  sample  collection  method  that
yielded the highest concentrations of measurable gut hormones consisted of using two
separate gut hormone collection tubes: 1) containing DPP-4 inhibitor and aprotonin for
glucagon sample collection and 2) containing DPP-4 inhibitor,  AEBSF and protease
inhibitor cocktail for all other gut hormone sample collection. Once samples had been
collected they were stored at -80°C prior to being processed. Our final choice of assays
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used to process these samples were: Millipore's human metabolic hormone panel for
active  ghrelin,  GIP,  leptin,  PP,  PYY and  c-peptide;  Mercodia's  glucagon  assay  and
Millipore's high sensitivity active-GLP-1 assay. 
All  collected  samples  were  processed  on  the  selected  assays  by  Dr  David  Hughes
(author  of  this  thesis)  according  to  the  manufacturers  recommended  protocol.  The
analysis of these results revealed that the plasma concentrations of GIP, leptin, PP, PYY
and active-GLP-1 were no different in individuals with type 1 diabetes compared to
healthy controls. However, the plasma concentrations of glucagon, active ghrelin and
PYY were different in type 1 diabetes. Stimulated glucagon levels were found to be
significantly higher in new onset type 1 diabetes, but then returned to levels similar to
those  of  healthy  individuals  as  duration  of  diabetes  increased.  Elevated  stimulated
glucagon levels in early type 1 diabetes lends some weight to the hypothesis that in
early stages of type 1 diabetes, alpha cells undergo a process of hypertrophy. It could
also point to a more focused role for the use of glucagon suppressing pharmacotherapy
in the initial years after diagnosis of type 1 diabetes. 
Fasting and stimulated active ghrelin plasma concentrations were found to be lower in
individuals with type 1 diabetes compared to healthy controls with a trend toward a
decrease  in  levels  of  ghrelin  with  the  duration  of  diabetes.  There  is  no  current
explanation for the lower plasma concentrations of active ghrelin in type 1 diabetes.
One could hypothesise that  the  lower  concentrations  are  due to  a  isocaloric  dietary
change that occurs shortly after diagnosis. These changes would need to be isocaloric as
the lower active ghrelin concentrations present in patients with type 1 diabetes did not
appear to correlate with BMI or eating behaviour.
135
The fasting PYY plasma levels, but not stimulated PYY levels, were higher within the
first 2 yrs duration of type 1 diabetes compared to healthy individuals. These elevated
levels then declined to  levels similar  to healthy individuals as duration of diabetes
increased. These elevated fasting PYY levels seen in early onset type 1 diabetes could
merely have occurred through chance or possibly by confounding influences on our data
(e.g. age). The data from healthy individuals suggest that PYY correlates to ageing and
uncontrolled eating behaviour. As eating behaviour data was not collected from ExTOD
study participants we are unable to determine the impact this has on recent onset type 1
diabetes.  However,  data  from  individuals  with  negative  c-peptide  type  1  diabetes
showed no significant correlations between PYY and either ageing or eating behaviour.
Results from other studies have shown that oral glucose stimulates an initial 20 minute
paradoxical rise in plasma glucagon concentrations, which is not present when the same
quantity of glucose is give intravenously. We hypothesised that this paradoxical rise in
glucagon levels could be mediated by other gut hormones. However, the analysis of the
initial  30  minute  change  (Δ30  min)  in  glucagon  levels  did  not  identify  a  sole  gut
hormone  that  significantly  correlated  across  each  individual  cohort  population.
Moderate  correlations  for  GLP-1,  PP and  ghrelin  were  identified,  but  in  different
participant  groups.  When the cohorts  were combined then only ghrelin  significantly
correlated with Δ30 min in glucagon level but with a weak strength (r=0.3). The lack of
correlation  between  glucose  and  c-peptide  with  Δ30  min  in  glucagon  suggest  that
glucagon  may  initially  be  controlled  through  a  non-glucose,  non-insulin  dependent
mechanism, possibly originating from within the gut. Altogether, these results pose the
hypothesis  that  the  initial  30  minutes  paradoxical  rise  in  glucagon  may  be  due  to
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glucagon being released from a sub-population of glucagon secreting enteroendocrine
cells located in close proximity to the ghrelin secreting cells in the stomach.  
The next key objective was to explore the effect of the loss of endogenous insulin in
type 1 diabetes on correlations between factors that influence appetite and gut hormone
concentrations. Results from ours and other studies confirm the significance of leptin as
a biomarker of sedentary lifestyle, body mass index and emotional eating in the general
population. Our results also show that leptin is  an important biomarker of body mass
index in individuals with type 1 diabetes. Also new correlations between uncontrolled
eating behaviour and stimulated GIP and PYY were found in healthy volunteers, but not
in those with type 1 diabetes, although GIP did correlate with sedentary lifestyle and
ageing in type 1 diabetes. Together these results suggest that there may be a role for GIP
as  a  biomarker  for  physical  inactivity  and  uncontrolled  eating  behaviour.  Whilst
elevated GIP is associated with insulin resistance in type 2 diabetes, it may also have a
function linking lifestyle to the pathogenesis of type 1 diabetes. To better understand
this relationship between GIP and modifiable lifestyle factors in type 1 diabetes then
future research should also consider GIP's role in glycaemic control. 
The final objective was to develop a method to explore the histopathological changes of
alpha cells in type 1 diabetes. This was only going to be achieved through the use of
samples  collected  through  the  'Juvenile  Diabetes  Research  Foundation  network  for
Pancreatic  Organ  donors  with  Diabetes' database.  Initial  searches  revealed  that  the
number of available pancreatic samples stained for glucagon taken from donors with
type 1 diabetes was lower than first expected. This, along with the lack of appropriate
online  image  manipulation  software,  posed  a  significant  obstacle  in  determining
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whether the duration of type 1 diabetes affected the quantity of functional alpha cells. In
order  to  overcome the  software  problem,  methods  more  commonly  used for  digital
photographic enhancement were refined and utilised. In total sixteen donor slides from
the  database  were  analysed.  No  correlation  was  found  between  duration  of  type  1
diabetes and area of glucagon staining, but a moderate correlation was detected between
age and area of glucagon staining. This suggests that the area of glucagon stained alpha
cells maybe a marker of ageing and not of duration of type 1 diabetes. What it is not
possible to deduce is whether an individuals age, BMI or duration of type 1 diabetes can
be used to determine the number of alpha cells present for any future gene manipulation
therapy to regenerate beta cells from alpha cells. However, due to the small sample size
in this analysis, it would be prudent to remain cautious about conclusions until either the
database expands or other acceptable means of quantifying alpha cell numbers can be
found.
Apart  from the  key  findings  already  discussed  the  results  from  this  research  have
opened up new interesting avenues for future research. Firstly, the analysis of c-peptide
levels in those with diabetes duration under 2 years raises the possibility of a 30 minute
stimulated c-peptide level being used to aid in the diagnosis of type 1 diabetes in those
clinically ambiguous cases involving obese young individuals. Secondary, the incretin
analysis brought to light the possibility that stimulated incretin levels could potentially
be used as a marker of gut transit time, which would reduce the need for xray exposure.
Thirdly, the findings of elevated stimulated glucagon or reduced active ghrelin in those
with  less  than  two  years  duration  of  type  1  diabetes  suggest  a  possible  role,  in
combination with other biomarkers, in the early diagnosis of type 1 diabetes potentially
prior to the onset of hyperglycaemic symptoms. 
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In summary, this research has furthered our understanding of the relationship of gut
hormones and alpha cells in the pathophysiology of type 1 diabetes. It has shown that
type 1 diabetes may cause significant changes to plasma concentrations of some gut
hormones (i.e. active ghrelin, glucagon and PYY) and that lifestyle factors can impact
on their levels (i.e. GIP and leptin). It has also highlighted the need for further research
into  understanding  the  interplay  between  gut  hormones,  lifestyle  factors  and  the
homoeostatic control of glucose in type 1 diabetes. 
Finally, whilst this thesis has focused on the role gut hormones play in the arena of
glucose homeostasis in type 1 diabetes, there are areas of interest outside of this domain
which  are  relatively  devoid  of  research.  Important  questions  remain  unanswered,
including, but not limited to the impact of gut hormones on inflammation, mental health
and child development in type 1 diabetes.  
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8. Appendix 4 – Publications and Presentation Abstracts
Publications & Presentations related to this thesis.
British Journal of Diabetes and Vascular Disease 2014;14:45-51 
Title: Alpha cell function in type 1 diabetes
Author: D. Hughes & P. Narendran
From: Centre of Endocrinology, Diabetes and Metabolism, Institute of Biomedical 
Research, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
Abstract
Our understanding of the pathogenesis of Type 1 Diabetes (T1DM) has traditionally 
revolved around the insulin deficiency that follows pancreatic beta cell loss. However, 
there is an increasing appreciation of defect in other gluco-regulatory cells in T1DM. 
Over secretion of glucagon from pancreatic alpha cells is characteristic of T1DM, and 
modulating these glucagon levels reduces hyperglycaemia. This article reviews alpha 
cell function in T1DM. We examine how its function is controlled and compromised, 
and review studies that target alpha cell function. Finally, we explore potential 
approaches to modulating alpha cell function in T1DM.
Presentation Abstract - Diabetes UK Conference April 2015 
Poster: 171
Title: Physiological levels of gut peptides are different in individuals with type 1 
diabetes compared to healthy volunteers.
Author: D. Hughes, P. Narendran
From: Centre of Endocrinology, Diabetes and Metabolism, Institute of Biomedical 
Research, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
Introduction
A wave of novel drugs that modulate gut peptides are being developed for the treatment 
of type 2 diabetes and obesity. The modulation of these peptides can alter insulin 
resistance, insulin secretion and satiety. However, these drugs may have a role in 
treating type 1 diabetes. However, the physiology of these peptides may be different in 
type 1 diabetes. This study set out to determine whether the physiological levels of gut 
peptide levels in individuals with type 1 diabetes is different to healthy volunteers.
Methods
Participants were recruited from the CDR-Diabetes study (REC:12/WM/0089) and 
ExTOD study (REC:10/H1206/4). Participants underwent a two hour mixed meal test. 
Analysis of Leptin, Ghrelin, PP, PYY, C-Peptide & GIP were performed using Luminex 
xMAP. Active-GLP1 & Glucagon analysis was performed through ELISA.
Results
A total of 24 healthy volunteers samples were analysed and 48 participants with type 1 
diabetes.  Area under the curve were analysed between healthy controls and those with 
type 1 diabetes. Unpaired T-test analysis was performed to determine if there were a 
significant difference between the groups: C-peptide (p<0.001), Glucagon (p<0.01), 
active GLP-1 (p=0.15), GIP (p=0.23), Active-Ghrelin (p<0.001), Leptin (p=0.73), PP 
(p=0.46) & PYY (p=0.95).
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Conclusions
C-peptide and ghrelin levels are significantly lower in type 1 diabetes. Glucagon levels 
were significantly increased in type 1 diabetes.  Levels of GLP-1, GIP, Leptin, PP & 
PYY were not significantly different. These differences in physiological gut peptide 
levels will need further research to determine their potential as therapeutic targets.
Publications & Presentations not-related to this thesis, but research related:
British Journal of Diabetes and Vascular Disease 2016 – In Press
Title: Elevated serum free light chains predict cardiovascular risk in type 1 diabetes 
mellitus.
Author: Lauren Marie Quinn, Sheridan McWilliam, John P Campbell, Yan Wang, David
Hughes, Mark T Drayson & Parth Narendran.
From:  University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
Abstract
Aims: Increased serum polyclonal combined immunoglobulin free light chain (cFLC = 
FLCκ+FLCλ) predicts cardiovascular (CV) events in South-Asians with type 2 diabetes 
mellitus. We examined whether cFLC also predicted CV risk in unselected patients with
type 1 diabetes mellitus.
Methods: cFLC was estimated in the serum of 55 adults with type 1 diabetes mellitus. 
CV risk was measured through two validated risk engines–Q-Risk and PROCAM. 
Statistical association was tested using the parametic Pearson’s or the Spearmans’-
Rank-Correlation-Coefficient test, student t-test or Mann-Whitney-U test and Kruskall-
Wallis test for parametric or non-parametrically distributed data accordingly.
Results: cFLC was associated with CV risk. This association was significant when 
estimated through either risk engine (PROCAM p=0.003, Q-Risk p=0.012). cFLC was 
associated with diabetes mellitus duration(p=0.003), age(p=0.006), and history of 
cardiac disease(p=0.042).
Conclusions: These findings indicate that cFLC is a marker of CV risk in people with 
type 1 diabetes mellitus. Moreover, it supports emerging data demonstrating cFLC as a 
prognostic indicator for mortality.
Presentation Abstract - ABCD Spring Meeting 2013
Poster number: 2
Title: Risk of Obstructive Sleep Apnoea (OSA) is increased in type 1 diabetes (DMT1): 
Preliminary results from the Chronic Disease Research in Diabetes Study
Author: Dr Neeral Patel, Dr David Hughes, Jayne Robbie & Dr Parth Narendran
From: Centre of Endocrinology, Diabetes and Metabolism, Institute of Biomedical 
Research, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
Introduction
The Chronic Disease Research in Diabetes Study commenced in November 2012. It 
aims to develop a database of clinical information paired with biological samples to 
explore the natural history of diabetes and its complications. Here we present early data 
on risk of OSA, depression, functional ability and eating behaviour in DMT1 and type 2
diabetes (DMT2).
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Methods
Participants completed the following validated questionnaires at their baseline visit: 
STOP screening questionnaire for OSA, Patient Health Questionnaire (PHQ-9) for 
depression, Health Assessment Questionnaire (HAQ-DI) for functional ability, Three 
Factors Eating Questionnaire (TFEQ-R18) for eating behaviour. Anthropometric 
measurements including neck circumference were also collected.
Results
30 subjects have been recruited to date. 62% with DMT1 and 38% with DMT2. The 
STOP score for OSA was higher (p=0.026) for individuals with DMT2 than DMT1, 
with the overall risk being increased for both conditions. Neck circumference was 
positively correlated with the STOP risk scores for OSA (p=0.047). No significant 
difference between DMT1 and DMT2 existed for PHQ-9 depression scores (p=0.072), 
HAQ-DI functional ability scores (p=0.113) or any domains for TFEQ-R18 eating 
behaviour questionnaire: cognitive restraint (p=0.730), uncontrolled eating (p=0.601) 
and emotional eating (p=0.797).
Conclusions
We present preliminary data related to co-morbidities in individuals with diabetes. Early
results suggest a yet unexplored risk of OSA in individuals with DMT1, and a trend 
towards increased risk of depression inDMT2 compared to DMT1. 
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Title: Should diabetic patients be routinely screened for obstructive sleep apnoea?
Author: Dr Neeral Patel & Dr Samaresh Mazumdar
Supervisors: Dr David Hughes & Dr Parth Narendran
From: Queen Elizabeth Hospital, Birmingham, UK.
ABSTRACT
The Chronic Disease Research in Diabetes Study (CDR-Diabetes) commenced in 
November 2012. It aims to develop a database of clinical information paired with 
biological samples to explore the natural history of diabetes and its complications. Here 
we present early data on risk of obstructive sleep apnoea (OSA) in type 1 (DMT1) and 
type 2 diabetes (DMT2). Participants completed the STOP-Bang screening 
questionnaire for OSA. Anthropometric measurements were also collected to allow 
calculation of visceral adipose tissue (VAT). Thirty-five subjects have been recruited to 
date. The STOP-Bang score for OSA was higher for individuals with DMT2 (mean 
STOP-Bang=5.30±1.16) than DMT1 (mean STOP-Bang=3.24±1.72, p=0.0016). Overall
risk was increased for both conditions, with mean STOP-Bang scores greater than 3 as 
the threshold for moderate-to-high risk of OSA. There is strong positive correlation 
between VAT and STOP-Bang score (Pearson r value=0.844; p<0.001). Preliminary 
results from this, the first reported use of STOP-Bang questionnaire in the diabetic 
population suggests an as of yet, unexplored risk of OSA in individuals with DMT1.
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Poster number: P224
Title: An improved indicator of risk for obstructive sleep apnoea: estimated visceral 
adiposity compared to body mass index and waist-hip ratio in individuals with diabetes.
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From: Centre of Endocrinology, Diabetes and Metabolism, Institute of Biomedical 
Research, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
Introduction
Obstructive sleep apnoea (OSA) is strongly associated with central obesity and type 2 
diabetes. Central obesity is caused by an increase in visceral adipose tissue. Visceral 
adiposity can be accurately measured with CT, MRI or DEXA scans. The recent 
publication of a formula to estimate visceral adiposity (eVA) could provide a new 
inexpensive means to determine risk of obstructive sleep apnoea. 
Methods
Participants with diabetes were recruited to the CDR-Diabetes study (an ongoing, 
observational, multi-centred study). As part of the study, body mass index (BMI), 
Waist:Hip ratio and estimated Visceral Adiposity (eVA) were recorded. Also, 
participants completed the validated STOP-BANG screening tool for OSA. A STOP-
BANG score of >3 is considered moderate-high risk of OSA.  SPSS statistical software 
was then used to determine correlation coefficients and statistical probability.
Results
A total of 31 participants were analysed (type 1 diabetes=21, type 2 diabetes=10). The 
mean STOP-BANG score was 3.88. The correlation coefficient values for STOP-BANG
scores were: BMI=0.616 (p<0.01), Waist-Hip ratio=0.696 (p<0.01) and eVA=0.852 
(p<0.01). Sub-group analysis of those individuals with type 1 diabetes: eVA=0.809 
(p<0.01).
Conclusions
BMI, Waist-Hip ratio and eVA  all significantly correlate to risk of OSA. eVA correlates 
stronger to OSA risk than either BMI or Waist-Hip ratio (even in indiviudals with type 1
diabetes). Further research is required to determine whether eVA has a role as a 
diagnostic tool for obstructive sleep apnoea.
Poster number: P174
Title: Free light Chains are a biomarker for cardiovascular disease in patients with type 
1 diabetes
Author: LM Quinn*, S McWilliam, JP Campbell, D Hughes, MT Drayson, P Narendran
From: Centre of Endocrinology, Diabetes and Metabolism, Institute of Biomedical 
Research, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
Aims: Light chains (kappa and lambda) are integral components of immunoglobulins 
that are synthesised in excess by plasma cells and filtered by the kidneys. Polyclonal 
free light chains (FLC) are frequently elevated in patients with renal disease or immuno-
stimulatory disorders. Elevated (combined) polyclonal FLC have also been 
independently associated with morbidity and mortality in the general population, and 
more recently with cardiovascular disease (CVD) in patients with type 2 diabetes. We 
aimed to investigate whether FLC associated with CVD risk in patients with type 1 
diabetes.
Methods: CVD risk was estimated in a cohort of 55 patients with type 1 diabetes from 
the West Midlands chronic disease research database (CDRD) using the Procam and Q-
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risk CVD risk engines. FLC was determined using a monoclonal-antibody based assay. 
Non-parametric statistical analyses were performed to determine whether FLC 
associated with CVD risk.
Results: Our cohort consisted of male and female, predominantly white British patients, 
mean age 48 years. FLC kappa/lambda ratio was normal for our cohort. Q-risk 10-year 
score and Procam Myocardial Infarction risk scores were both significantly associated 
with FLC (p=0.003 and p=0.012 respectively), as well as duration of diabetes 
(p=0.003), patient age (p=0.006) and medical history of cardiac disease (p=0.042).
Summary: We show that CVD risk is significantly associated with FLC in patients with 
type 1 diabetes. The mechanisms linking FLC with CVD risk remain unclear. Elevated 
polyclonal FLC are associated with inflammation, which in turn is associated with CVD
risk. Alternatively FLC may be atherogenic and predispose to coronary artery disease.
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Title:  Who Volunteers for Research into Type 1 Diabetes? Implications for Exercise
studies.
Author: Jeyaraman, M Charlton*, D Hughes, P Narendran
From: Diabetes Research Unit, Queen Elizabeth Hospital, Birmingham, UK
Aim: To describe obstacles to exercise in a group of research volunteers with type 1
diabetes.
Introduction: Recruiting to research into exercise is challenging.  Previous work has
identified motivation as a barrier to participation.  We looked at characteristics of people
with type 1 diabetes who are motivated to take part  in research and examined their
difficulties with exercise.
Methods: The Chronic Disease Research into Diabetes (CDRD) study is open to all
people  with  diabetes  attending participating  centres.  Exclusion  criteria  are  minimal.
Baseline data from recruits with type 1 diabetes at one centre are presented.
Results:  71 volunteers for CDRD with type 1 diabetes were identified.  46.5% were
female,  median  age  50  years  (IQR 34-58);  91.5% caucasian.  12% obese.  85% had
diabetes  >10  years'  duration.  Insulin  was  69%  basal-bolus,  24%  pumps.  27%  had
HbA1c ≤58 mmol mol-1, 10% ≥ 100. 8.5% currently smoked. 48% were employed or
studying. 66.2% reported >2 hours of recreational screen time daily. Exclusion criteria
for exercise trials were quantified: foot ulcers 1%; amputation 1%; blood pressure over
180/100 3%; active proliferative retinopathy 8%; beta-blockers and other rate-limiting
treatment 11%. 23% had musculoskeletal co-morbidities and 18% respiratory.
Validated questionnaires showed: 35% moderate or extreme anxiety/depression; 29%
breathless walking or hurrying; 27% had mobility difficulties and 35% pain sufficient to
affect quality of life; 33% had difficulties in activities of daily living.
Conclusions:  People  with  type  1  diabetes  who are  most  motivated  to  participate  in
research have significant physical and psychological barriers to exercise.
When designing clinical trials into exercise in type 1 diabetes researchers need to adapt
their interventions or recruitment strategies accordingly.
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Author: D Jeyaraman*, M Charlton, P Kempegowda, M Jain, D Hughes, P Narendran
From: Diabetes Research Unit, Queen Elizabeth Hospital, Birmingham, UK
Aim: To describe the  characteristics  of  a  group of  research  volunteers  with  Type 1
Diabetes and compare them with a clinic population.
Methods: The Chronic Disease Research into Diabetes (CDRD) study is open to all
people  with  diabetes  attending participating  centres.  Exclusion  criteria  are  minimal.
Baseline data from recruits with type 1 diabetes at one centre were compared with non-
research clinic attenders in order to define characteristics of people who are motivated
to take part in research.
Results: Of 153 volunteers in CDRD, 71 had type 1 diabetes. Controls were an internal
audit of 71 consecutive clinic attenders with type 1 diabetes.
Gender and ethnicity were similar in both groups as were HbA1c and insulin regimen.
Volunteers'  median  age  was  50  years  (IQR  34-58)  and  controls'  38  (27-49).  12%
volunteers (19% controls) had BMI > 30. Volunteers' median blood pressure was 133/77
(controls' 133/83). 58% (controls 39%) had diabetes of 20 years' duration or longer.
Comorbidities were predominantly musculoskeletal affecting 22.5% (controls 6%) and
respiratory 18.3% (8%); 4% (3%) had cardiac disease. Only 17% volunteers had no
pertinent comorbidities but 45% controls. Polypharmacy was common with mean 3.86
non-insulin drugs per volunteer (1.6 per control).
Conclusions:  From  a  clinic  population  of  people  with  type  1  diabetes,  research
volunteers were older and had diabetes of longer duration than average. They took more
prescription medication and had more comorbidities, particularly musculoskeletal and
respiratory.
In designing clinical trials, researchers need to be aware that people motivated to take
part may not be representative of the pool from which they are recruiting.
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